🇺🇸 USA — DEA Schedule III registration portal opens (~400 filings); FY2026 caps intoxicating hemp at 0.4 mg/container effective 12 November

🔭 On the radar: Expedited DEA hearing on marijuana rescheduling opens 29 June (60-day filing, ~6-month review). Treasury/IRS §280E retroactivity guidance pending; TerrAscend $8.4m refund appeal next. 12 November 2026 hemp-THC cap subject to Senate Farm Bill amendment. Trulieve BC→Delaware domestication vote 5 August.

🏛️ Regulation — DEA Schedule III portal draws ~400 filings; FY2026 appropriations cap hemp-THC at 0.4 mg/container; HHC listed on Schedule I

• DEA extended Schedule III registration forms to state-licensed cultivators, manufacturers, distributors and testing labs; ~400 state-licensed filings in the first 2 weeks after 29 April opening; 60-day window, approval mandated within ~6 months. State-medical-licensed marijuana formally falls under Schedule III.
  • Congressional Research Service sidebar (30 April): medical operators must register with DEA to be Schedule III compliant; 12-year-old §280E appropriations rider becomes redundant for registrants but contingent on annual renewal.
  • Verano Holdings submitted Schedule III applications across cultivation, manufacturing and testing facilities on 13 May.
  • Trulieve Cannabis filed registration applications for 206 dispensaries on 7 May; BC → Delaware domestication announced 13 May (shareholder vote 5 August 2026, record date 8 June; 240 retail sites, 204 DEA-registered dispensaries).
• DOJ told the District of NJ that TerrAscend USA must repay its $8.4m refund plus interest — IRC §280E barred the original 2020 deduction. Treasury/IRS amended-return guidance pending; MJBizDaily flags a multi-billion-dollar swing factor for 2026 MSO cash flow.
• DOJ’s Schedule III final order narrows the perimeter to state-legal medical operators: interstate commerce, banking and FD&C Act requirements unchanged; Treasury, FDA and DEA compliance guidance pending.
  • TSA updated its ‘What Can I Bring?’ tool on 27 April to permit medical marijuana in baggage; no Special Instructions on documentation, quantity or interstate travel — discretion with officers and state law.
  • EPA may reopen the FIFRA §24(c) pesticide pathway for cannabis under Schedule III; ~100 EPA-approved hemp pesticides exist but none for marijuana.
  • House Appropriations Committee advanced an amendment to let VA physicians recommend cannabis on 13 May; next: House floor vote.
  • The Cannabist Company received Chapter 15 recognition on 9 May (Judge Brendan Shannon, District of Delaware, Case 26-10426) — first cannabis MSO with US federal cross-border bankruptcy protection; liabilities ~US$270m, senior secured notes ~US$179m, US$51m IRS claim; Fox Rothschild notes CCAA side-door entry after $130m Virginia, $47m Ohio and $16.5m Delaware asset sales.
• P.L. 119-37 (FY2026 appropriations) caps intoxicating hemp at 0.4 mg total-THC/container effective 12 November 2026, banning products with unnatural/synthesised cannabinoids; US Hemp Roundtable: $28.4 bn industry, ~300,000 jobs at risk. Sen. Rand Paul (R-KY) called the cap ‘the most thoughtless, ignorant’ proposal he had seen.
  • DEA listed hexahydrocannabinol on Schedule I under drug code 7220 (effective 4 May, 91 FR 23913): synthetic and hemp-hydrogenated HHC does not qualify as ‘tetrahydrocannabinols in hemp’ under the 2018 Farm Bill.
  • ONDCP 2026 National Drug Control Strategy (4 May): delta-8, delta-10, THC-O and THCP flagged as Schedule I under November 2026 ‘Hemp Restriction’ regulations; alarm raised over alleged cannabis–psychosis links and ‘Big Tobacco-style’ youth marketing.
  • FBI raided a Virginia hemp shop tied to a state lawmaker on 12 May — first high-profile federal enforcement against intoxicating-hemp retail this year.
  • Judge McFadden (DDC) dismissed the SAM-led lawsuit challenging the Medicare hemp coverage pilot on Article III standing grounds, preserving the December 2025 EO programme ($500/year cap, ≤0.3% delta-9, ≤3 mg THC/serving, no inhalables).
• California DCC streamlined licence-designation switching on 1 May: removed renewal-wait and local-authorisation requirements so cultivators can opt into the medical pathway for §280E relief.
• Georgia Gov. Brian Kemp signed a medical cannabis expansion bill on 13 May: authorises vaping, adds new qualifying conditions, replaces the restrictive THC potency cap.
  • Idaho’s medical cannabis ballot campaign submitted ~2× the required signatures on 8 May to qualify a 2026 ballot measure.
  • Texas DSHS rescinded Cresco Labs’ TCUP licence on 11 May — one of three vertically integrated permits under the recently expanded framework.
  • Maryland Cannabis Administration submitted a NOPA on packaging and sublingual pouches to the AELR committee on 18 May; 30-day formal comment opens with Maryland Register print end of June.
• Minnesota Legislature passed the 2026 cannabis omnibus (HF4203/SF4401; House 92–42, Senate 34–33): macrobusiness licence effective 1 January 2027 (38,000–45,000 sq ft canopy, 8 retail stores, 90,000 lb mfg cap), merges medical and adult-use supply chains; social-equity ownership cap 10%→33%; awaits Gov. Walz’s signature.
  • Illinois General Assembly passed SB 3222 on 1 June: doubles adult-use possession to 60g flower / 10g concentrates / 1,000 mg THC; raises craft cultivator canopy 5,000→14,000 sq ft; 0.4 mg THC/container hemp cap; drive-through sales and telehealth certifications allowed; awaits Gov. JB Pritzker signature.
  • Pennsylvania Senate committee advanced a Cannabis Control Board bill on 9 May (Sen. Dan Laughlin, R-Erie): moves medical oversight from DOH and brings intoxicating hemp under state regulation.
  • Virginia General Assembly rejected Gov. Spanberger’s 40+ amendments to HB642/SB542 (Senate 21–18, House voice vote, 22 April); original bill (1 January 2027 launch, $10m licence fee, 350-store cap, 6% excise) back on governor’s desk.
  • New York CCB approved 32 new adult-use licences on 7 May: total 2,259 (56% SEE); $553m YTD sales through April; 4/20 week $37.9m (+20% YoY) across 655+ dispensaries.
• Arizona repeal organisers abandoned the 2026 ballot effort on 7 May, removing existential ballot risk from the state’s $1bn+ adult-use market.
  • Massachusetts Special Joint Committee recommended no action on the adult-use repeal measure on 12 May; organisers need 12,429 further certified signatures by 1 July to qualify for the November ballot.
• Colorado MED privately told industry that illegal hemp-derived sales are ‘larger than we can quantify’ (Denver Gazette/ProPublica audio, 15 May), depressing marijuana prices; MED emergency rules pending after 2026 legislative reform failed.
  • Connecticut General Assembly passed HB 5350 on 4 May: eliminates concentrate THC potency cap (effective 1 October 2026); creates up to 10 commercial extractor licences for >0.3% hemp-derived extracts; 30%-THC psychosis warning extended to all cannabis plant material.
  • Texas judge granted a TRO allowing THCA flower sales to resume on 5 May, conditioned on stricter testing, lab-certification and labelling requirements.
• Minnesota OCM suspended Legend Technical Services’ testing licence on 20 May, removing 1 of 4 licensed labs; market running ~2.5-week turnaround. Minnesota Court of Appeals overturned Albert Lea’s rejection of Smoking Tree microbusiness on 22 May — first state appellate ruling tying local cannabis-licensing discretion to the literal text of a city’s ordinance.
  • Massachusetts CCC launched a THC-potency labelling audit on 22 May: 75%–125% tolerance band (e.g. 11.25%–18.75% for a 15% label); products outside band may be withdrawn via administrative action.

💼 Market — Tier-1 MSOs return to GAAP profitability; Curaleaf 1-for-3 reverse split; national licence count –4% QoQ

• Curaleaf $324m Q1 revenue (+6% YoY): 49% gross margin, $63m adjusted EBITDA (20% margin), $70m GAAP net income ($0.09 EPS); international +35% YoY (Four 20 Pharma Germany). 1-for-3 reverse stock split announced 26 May (effective ~5 June 2026, TSX conditional): ~698.7M shares → ~232.9M ahead of US exchange uplisting.
• Green Thumb Industries $300.2m revenue (+7.4% YoY): 47.9% gross margin, $15.4m GAAP net income, $93.5m normalised EBITDA (31.2% margin), $76m operating cash flow; $33.3m share buyback (~6M shares, ~13.4M YTD); credit facility +$50m; effective tax rate 76.2% under §280E.
• Trulieve Cannabis $286.8m revenue, 59% gross margin: $100.4m adjusted EBITDA, $352.9m cash; 206 DEA Schedule III applications filed alongside results.
• Cresco Labs $151m revenue, 50.7% adjusted gross margin: $33m adjusted EBITDA (21.7%), $17m GAAP net loss; retained #1 share in multiple billion-dollar markets.
  • Ascend Wellness $116.9m net revenue (-3% QoQ): 46.1% adjusted gross margin, $26.3m adjusted EBITDA (22.5%); 51 stores scaling to ≥60 by year-end; Lansing MI facility suspended late Q2 for fire-incident remediation.
  • Jushi Holdings Q1 revenue +4% YoY to $66.4m: 45% gross margin (+460 bps), $19.8m net loss; refinanced $132.3m debt into $160m 12.5% term loan; ~60% medical revenue mix positioning for §280E relief.
• National cannabis-business licence count fell ~4% QoQ in Q1 2026 for a second consecutive year; cultivator and processor licences bearing the brunt. Wholesale flower spot-price range: $720/lb (Oregon) to $4,500/lb (Minnesota); US Spot Index $1,056/lb (Cannabis Benchmarks, 8 May).
• WM Technology Q1 revenue $43.6m (-2.2% YoY): $5.9m adjusted EBITDA, 4,983 monthly paying clients; voluntarily delisted from Nasdaq to OTC Markets (MAPS) to unlock plant-touching investment; $57m cash.
• FundCanna secured a senior credit facility of up to $60m ($35m funded at close) from a ~$40bn AUM institutional investor; total capital ~$75m; >$250m deployed across 5,000+ transactions to date; projects >$500m cumulative.
  • Apollo-managed funds agreed to acquire Emerald Holding and Questex for combined ~$1.5bn EV ($5.03/share cash for Emerald, 42.1% premium): creates ~160-event North American B2B platform including MJBizCon; close expected H2 2026.
• Target expanded hemp THC beverage sales to 300+ stores across Florida, Texas and Illinois, scaling from the original 72-store Minnesota pilot.
  • Nabis agreed to acquire Hudson Distribution Services’ NJ cannabis distribution licence on 4 May; Hudson + affiliates become Nabis shareholders; NJ wholesale platform launch planned H2 2026. Nabis: ~$1.5bn annual licensed cannabis deliveries (Forbes, 29 May) across 4 US states.
  • Mindset Capital reported >12% stake in Leef Brands (EV ~$75m) on 27 May; projected $15m/year cash flow once Salisbury Canyon Ranch activates; each $0.10/g rise in distillate price adds ~$7m annual cash flow (NJ prices $7/g above CA).
• Cronos Group Q1 net revenue +40% YoY to $45.2m: $19.2m gross profit (+39%), $15.7m net income (+103%), $822m cash; record Israel and international sales; PEACE NATURALS #1 brand in Israel for 9th consecutive quarter; #1 vape share in Canada.
  • Organigram Global Q2 FY26 net revenue –9% YoY to $59.8m on lower vape and infused pre-roll sales.
• Massachusetts CCC $7.32m in adult-use sales on 4/20/2026 — first 4/20 under the newly doubled 2 oz daily purchase limit (signed 19 April); 900 over-1-oz orders worth $117,067 across 19–20 April.
  • Ohio adult-use sales $1.12bn TTM through March 2026 (+35% YoY): flower $588m (+35%), vapor pens $291m (+36%), edibles $139m (+35%); pre-rolls $7.4m/month (33× growth in 8 months); disposable vapes overtook cartridges in February.
• JIRS Paris and Versailles Gendarmerie SR indicted five suspects in an alleged California-to-Europe trafficking network on 23 May: 430 kg seized across 4 air-freight shipments; 21 shipments estimated since June 2025; one concealed 30 kg in an arcade console.

🔬 Science — Cannabis-tobacco co-use: 2.93× psychosis conversion risk (NAPLS2, n=1,012); NY OCM launches first state-led IBD study

• UC Riverside Center for Cannabinoid Research reported whole-plant cannabis extract outperformed THC alone in an obesity mouse model (12 May): restored fat-pancreas insulin signalling and improved glucose tolerance.
• Daniel K. Fowler, Tylor M. Savage and Duncan I. Mackie published a BMC review of CBD, CBG, CBC and varin analogues as microglial modulators (Journal of Cannabis Research, 13 May; DOI 10.1186/s42238-026-00445-5) across Alzheimer’s, Parkinson’s, MS and Huntington’s disease; persistent translational gaps flagged for cannabinoids beyond CBD.
  • Mark Scialdone disclosed WIPO patent WO2025255098A1 on eleven fluorinated phytocannabinoids (9F HHC, 9F HHCA, 9F HHCV) on 30 May: synthesis yields 86%–98%; Jurkat assays show cell death at 72 h; NCI-60 anticancer activity claims via LinkedIn.
• New York State OCM launched the first US state-led observational clinical study on 13 May: oral CBD + Δ9-THC for quality of life in adults with moderate IBD; PI Dr Nakesha Abel; dispensing partners Vireo Growth and GTI.
  • University of Michigan / MoreBetter 12-week improvements across all three cannabinoid formulations (n=164: fibromyalgia, RA, OA; Clinical Therapeutics, 15 May); non-intoxicating CBD+CBDa provided pain and sleep relief without intoxication.
  • JAMA Network Open Colorado older-adults study (n=169; mean age 70.8; 8 May): 57.5% preferred THC+CBD edibles, 28.7% CBD-only, 13.8% THC-only; motivation centred on avoiding pharmaceuticals.
• Bello, Blyth, Ward et al. Nature Mental Health (12 May): heavy cannabis + light tobacco co-use associated with 2.93× hazard ratio for psychosis conversion (NAPLS2, n=1,012; 734 clinical high-risk; 95% CI 1.23–6.97, P=0.015); more frequent use linked to greater symptom severity across multiple domains.
  • Amy Cohn et al. (Stephenson Cancer Center / NIDA): 3,488 past-30-day cannabis users in Oklahoma (Clinical Therapeutics, 15 May): 76.2% tobacco co-use; combustible modes linked to higher respiratory-symptom severity; edibles ranked second among exclusive cannabis users.
• Multistate compliance-testing analysis across 11 states: mycotoxin failure rates 0.016% (flower) / 0.017% (concentrate) across 443,000+ samples (Clinical Therapeutics, 17 May); ochratoxin A most common; Fusarium-derived toxins remain off current panels.
  • Sang Choi argued in Clinical Therapeutics (15 May) that NY’s Compassionate Care Act pharmacist-in-dispensary requirement since 2014 reduces dosing errors — a template as Schedule III brings cannabis into mainstream healthcare.

Country thesis (May 2026). CDU-led federal realignment under Bundesgesundheitsministerin Nina Warken and Drogenbeauftragter Hendrik Streeck tightens medical access (MedCanG in-person rule, end of GKV reimbursement) while conditionally opening a Pillar-2 commercial pilot pathway under BMEL — yet Q1 2026 BfArM data (50.539 t, +34% YoY), strong European-focused operator earnings, and FDA Breakthrough for Vertanical‘s full-spectrum VER-01 (Exilby) show the German demand engine and pipeline still scaling against the policy headwind.

🇩🇪 Germany — Conservative drug commissioner Streeck backs adult-use (Pillar-2) pilots in Berlin, Hannover and Frankfurt as BMG proposes ending GKV flower reimbursement and BfArM Q1 imports reach 50.539 t (+34% YoY)

🔭 On the radar: BMG/Bundesfinanzkommission GKV flower-reimbursement proposal pending Gesetzentwurf; MedCanG amendment (BT-Drs. 21/3061) in Bundestag committee, SPD revisions before plenary vote. First CanG evaluation autumn 2026. Vertanical VER-01 (Exilby) EU launch 2027 (EMA pending), US Phase 3 data 2027, NDA 2028.

🏛️ Regulation — BMG proposes ending GKV flower reimbursement; MedCanG amendment tightens prescribing; conservative drug commissioner Streeck backs Pillar-2 (adult-use) pilots

• BMG / Bundesfinanzkommission propose ending GKV reimbursement of cannabis flowers: €19/g pharmacy ceiling vs €5/g self-pay benchmark across roughly 1 million GKV patients. No Gesetzentwurf published yet.
  • VCA drafts counter-proposal (‘Die Cannabisblüte muss in der Apotheke bleiben’), citing 84.5% Rx drop in the Bloomwell Cannabis Barometer (n=3,528).
  • Apokix May 2026 pharmacist survey: 65% of German pharmacists assess Teillegalisierung negatively.
• MedCanG amendment (BT-Drs. 21/3061) advances through Bundestag committee on a contested in-person prescriber rule; legal experts call it unenforceable because foreign-based telemedicine stays outside its scope.
  • SPD spokesperson Carmen Wegge invokes ‘Struck’s law’ — signals substantial committee revisions before any plenary vote.
  • 130. Deutscher Ärztetag (Hannover, 21 May): formal ‘Stopp-Signal’ resolution passed against questionnaire-based online prescribing. Deutsches Ärzteblatt 11/2026 (20 May) editorial frames political action on cannabis as a physician priority ahead of the autumn CanG evaluation.
• Drogenbeauftragter Streeck signalled openness to a Pillar-2 commercial pilot pathway for Berlin, Hannover and Frankfurt under BMEL: resident-only, 25 g/week, 5 g/adult/day (age ≥25), advertising ban, scientific monitoring. BMEL pre-approval stage — no city designations issued yet. Cannabiswirtschaft member firms submit model-project proposals to BLE citing Swiss and Dutch pilot precedents.
• BfArM republishes revised Narcotics Foreign Trade Ordinance forms effective 6 March 2026 (published 8 May in the Bundesanzeiger), formalising the import/export permit workflow for every licensed operator.
• DHV filed a Normenkontrollantrag at the Bayerischer Verwaltungsgerichtshof on 24 May against Bavaria’s cannabis Park-Verordnung; builds on October 2024 Popularklage before the Bayerischer Verfassungsgerichtshof. Next step: VGH ruling, potential escalation to the Bundesverfassungsgericht.
• Amtsgericht Amberg acquitted a CBD hemp-flower trader under Germany’s ‘intoxication clause’ (acquittal 27 April; prosecutor withdrew appeal). Local precedent only — no BGH or Bundesverfassungsgericht certainty; 1% THC threshold proposal remains the open federal question.

💼 Market — BfArM Q1 imports 50.539 t (+34% YoY, –15% QoQ); Cantourage €20.6m revenue, 10.6% EBITDA margin

• BfArM Q1 2026 imports: 50.539 t medical cannabis (–15% QoQ, +34% YoY); TTM above 218 t. Origin: Canada 26,753 kg (53%), Portugal 10,342 kg, Denmark 3,338 kg; 3 domestic licensed producers, two with Canadian ties.
  • Remexian Pharma (High Tide): record 7.6 t in Q2 2026 (+21% QoQ, +49% YoY).
  • EU-GMP supply hub diversifying: Czechia briefly exceeded Portugal in Canadian export value in early 2026; Malta sources from Israel, South Africa and Canada.
• Cantourage Q1 2026: €20.6m revenue (+11% QoQ), €2.2m EBITDA (10.6% margin), €8.8m net cash. Geographic split: Germany 51.5% / UK 41.3% / Poland 7.3%.
  • Curaleaf: US$324m Q1 revenue (+6% YoY), 49% gross margin, $70m GAAP net income; Four 20 Pharma buyout completed 1 May.
  • Canopy Growth relaunches Tweed in Germany (3 MTL strains: Pablo’s Revenge, Dante’z Inferno, Frost’d Flakes); Decibel international revenue ×3 to C$9.6m (+330%), Q1 C$29.8m (+41% YoY).
  • IM Cannabis: Q1 C$8.7m revenue, C$2.5m net loss (G&A –22% YoY); two convertible notes totalling US$550k (10% OID, 8% coupon).
• Bioxyne / Breathe Life Sciences signed exclusive German supply agreement with ADREXpharma: US$50m over 2 years (US$25m minimum year 1, auto 12-month renewal).
  • Bedrocan launches Bedromed standardised formulation (spray + drops); German distribution from August 2026. Becanex PIEX 70% THC raw extract arriving summer 2026 under Berlin §13(1) AMG licence.
  • Herbal Dispatch: EU-GMP processing partnership in Portugal; permit time 6 weeks → 7 business days; shipped 298 kg to Germany in January.
• German medical market ≈€2 bn; projected to more than double by 2031 (Organigram CEO cite). M&A pipeline building across 100+ German import-licence holders; Enua–Deutsche Bank debt facility signals institutional capital entering the sector.
  • Organigram post-Sanity acquisition: Sanity revenue €9m (2023) → ≈€60m (2025), positive EBITDA; next steps France, Spain, Portugal, Netherlands.
  • Canify plans Catharos rollout via IhreApotheke 7,500-pharmacy network; MG Health Lesotho merger at MoU stage, IPO planned.
• Neuss (NRW): cannabis specialty shop with on-site use under Heinrich Heine University Düsseldorf as a scientific study. Die Zeit (ZEIT 19/2026) features Erfurt’s ‘Haus der Versuchungen’ — Europe’s sole cannabis exhibition house — ahead of the autumn 2026 CanG evaluation.

🔬 Science — FDA Breakthrough Therapy for Vertanical VER-01 (Exilby); Apotheke LUX 99 real-world poster (n=320)

• Vertanical (Munich, FUTRUE Group) won FDA Breakthrough Therapy Designation for VER-01 (Exilby) in chronic low back pain on 19 May — the first German cannabis-derived candidate to reach FDA Breakthrough status. Basis: two randomised Phase 3 trials (European arm in Nature Medicine, September 2025). EU launch 2027 (EMA pending), US NDA 2028. DKJ127 line selected from >500 genotypes.
• Apotheke LUX 99 presented a single-site analysis of 320 first-time chronic-pain dispensations at MCC Berlin 2026 (28–29 May): 53% women / 47% men; 66% GKV / 34% PKV-self-pay; dosage-form × gender association χ²(2) = 34.35, p<0.001; 12-year age gap between inhalable and oral users; flower THC 4 pp higher in male patients (p=0.007). Preliminary, single-site — not generalisable.

🇬🇧 UK — CQC issues UK-first warning notice to Alternaleaf (4,000+ patients) and coroner’s PFD lands against Curaleaf Clinic (May 2026)

🔭 On the radar: ENDOCAN-1 (NHS Lothian + NHS Grampian, CBD vs placebo, 100-woman RCT) opens enrolment 1 June. FSA CBD novel-food final authorisations delayed until autumn 2026. ACMD 50 µg THC per-unit recommendation: no implementing legislation laid. Industrial hemp 0.2%→0.3% threshold pending Home Office.

🏛️ Regulation — CQC issues UK-first warning notice to telemedicine prescribing platform Alternaleaf over MDT and governance failures; Devon Partnership issues UK’s first NHS inpatient CBPM policy; FSA CBD authorisations delayed

• The Care Quality Commission issued a UK-first warning notice to telemedicine prescribing platform Alternaleaf (AP14599, surfaced 14 May) after a July 2025 inspection citing breaches in safe care, governance and prescribing; CQC retained a “good” rating for responsiveness against 87% satisfaction.
  • Key failings: patient self-selection without guidance; no MDT review; one specialist with “no evidence of training or references” after six weeks; workloads “unmanageable or unsafe”.
• Fieldfisher‘s analysis of the coroner’s PFD report against Curaleaf Clinic (27 May) flagged four concerns: MDT records, out-of-date GP SCR, failure to contact third-party psychiatrists, continued prescribing as an obstacle to addictions care.
  • Curaleaf subsequently implemented NHS National Care Records Service access and explicit CMHT consent/non-objection before commencing CBPMs for patients under Community Mental Health Team care.
• The Royal College of Nursing Congress 2026 (Liverpool, 18–21 May) passed a Cheshire Branch motion framing the post-2018 landscape as a two-tier system; patients unable to afford private care risk self-medicating on unregulated products; calls for UK-wide research and equitable prescribing pathways under NICE NG144.
  • The Guardian‘s Kojo Koram quantified the access gap (14 May) via NHSBSA figures: 89,239 unlicensed CBPM prescriptions issued Nov 2018–Jul 2022; fewer than five from the NHS; 30+ private clinics now operating.
  • Devon Partnership NHS Trust approved SOP CD21 in May 2026 — UK’s first NHS-trust inpatient CBPM policy, allowing continuation including vaporised flower via dry-herb vaporiser; the NHS still cannot fund or supply unlicensed CBPMs, so patients arrange supplies through their private prescriber.
• FSA CBD authorisations delayed until autumn 2026 following the Scottish consultation: updated business guidance published 1 May adding Article 4 consultation requests and a switching-applications policy; non-exempt CBD products containing controlled cannabinoids require a Home Office licence under the MDA 1971; Northern Ireland follows EU Regulation 2015/2283 (no CBD food product yet authorised).
• Hemp Hound questioned the FSA’s eligibility-threshold application (6 May) using Pureis as a case study; the commentary compiles FOI disclosures and correspondence challenging the judicial robustness of the regulator’s “already addressed” stance on inconsistent application of the 13 February 2020 on-market threshold.

💼 Market — UK flower imports double to 30,062 kg in 2025; 60–75k active patients estimated; Cannabis Europa London anchors €1.5bn European thesis

• UK imports doubled to 30,062 kg in 2025 (Home Office FOI, released 10 April 2026); Cannabis Industry Council estimates 60,000–75,000 active patients mid-2026 — first supply/demand anchor: ~444 g per patient per year.
• The Cannabis Industry Council‘s first defensible UK patient estimate (15 May, Plantz × Cannavec.ai) reports 60,000–75,000 active patients in mid-2026 and ≈95,000 cumulatively, anchored on NHSBSA dispensing trajectory (659,293 items in 2024, +133% YoY); active-vs-cumulative methodology explicitly disaggregated.
  • Home Office FOI data dated 10 April 2026 show flower imports more than doubled to 30,062kg in 2025 (vs 14,992kg in 2024), with quarterly volumes rising from 5,285kg in Q1 to 11,810kg in Q4 — a run-rate implying ≈47,000kg full-year 2026 if sustained.
  • Direct Canadian shipments rose six-fold to 17,067 kg in 2025 (from 2,578 kg); Spain fell to 3,417 kg (Q4: 161 kg); Portugal 3,971 kg; Germany 1,404 kg; South Africa 1,345 kg; Switzerland, Czech Republic and Greece debuted as UK suppliers.
  • The two datasets reconcile: ≈30 tonnes of supply across ≈67,500 midpoint active patients yields a baseline of ≈444g per patient per year, anchoring the per-patient ARPU work every operator will run in H2 2026.
• Curaleaf Laboratories became the first licensed UK manufacturer of medical cannabis suppositories and pessaries (5 May, MHRA-approved facility, available on prescription from launch day under MD Richard Hodgson); dosage forms developed following specialist-register prescriber requests; addresses patients who do not benefit from inhalation or oral administration.
• Cantourage reported Q1 2026 revenue of €20.6m (+11.0% vs Q4 2025) with EBITDA at €2.2m (10.6% margin) and a €8.8m net cash position; the UK now contributes 41.3% of group revenue (Germany 51.5%, Poland 7.3%), supported by continued telemedicine investment in Can Clinic (UK) alongside Telecan (Germany).
• SOMAÍ Pharmaceuticals signed an exclusive UK partnership with IPS Pharma and Integro Clinics (27 May) covering the phased launch of three globally recognised cannabis brands “in the coming months,” combining SOMAÍ’s EU-GMP manufacturing and indoor cultivation (NovaSoma, Lisbon) with IPS Pharma’s MHRA-licensed distribution and Integro Clinics’ online consultation platform.
• Tilray Medical put Director of International Medical Affairs José Tempero on the 26 May ‘Evidence First’ panel and co-hosted the afterparty with Lyphe Clinic — confirming the April 2026 Lyphe Group acquisition has been integrated into Tilray Medical’s UK-clinic-plus-EU-GMP-supplier positioning across 20+ regulated markets and 40+ brands.
• Cannabis Europa London (27 May): European market thesis at €1.5bn+; Deutsche Bank confirmed lending open above €20m revenue; Bloomwell‘s Kouparanis mapped four consolidator archetypes at ~6× EBITDA (wholesale) and 10–15× (tech/patient-platform), earn-outs typically ~50% of transaction value.
• The Business of Cannabis Awards 2026 confirmed Curaleaf’s dominance (250 entries, 8 countries): Clinic, Team and European Company of the Year; Bloomwell won Consumer Technology Provider and Business Leader (Kouparanis).
  • Carola Perez won the inaugural Hannah Deacon Award (presented by MP Tonia Antoniazzi); Village Farms took Producer of the Year; Cantourage received a special mention.
• Derek Chisora and Grow Group’s Pierre Van Weperen launched WarOnPain — UK’s first high-profile-athlete-fronted patient-education platform, citing the 8m NHS waiting list for pain and mental health.
  • Day 2: Arjan Roskam’s post-harvest critique (“9 out of 10 producers drying in 6–8 days when 14 are needed”) and launch of Cannabigator, a dual patient-and-clinician cannabinoid-recommendation app.
• Hystelica CSO Dr Grace Blest-Hopley argued at Cannabis Europa London that the UK product mix is “almost entirely high-THC flower” and that emerging suppositories are “designed by men without adequate lived experience”; EFSA designated CBD a reproductive toxin in the same week (THC already so classified).
  • Cannabis Health News reported the WCP framework launch (20 May); FORI founder Dr Suzanne Mulvehill anchored the Cannabis Europa London women’s-health closing panel (27 May); the framework extends CBPM policy into neurological regulation, sexual health and quality of life.
• 🇯🇪 Jersey turned its first cannabis-industry profit (Health and Care Jersey FOI): £12m revenue, ~£50m cumulative investment, 6,786 kg exports (×3 YoY), GB & NI shipments +348%.
• Northern Leaf accounts for ≈90% of Jersey production and supplied 3,590 kg to Germany alone — the largest UK-jurisdiction exporter into the German market.
• Local producers Green Island Growers and Caprica reached GMP Part One certification but cannot yet obtain manufacturing licences; Health and Care Jersey confirmed the current framework was not sufficiently robust and work had begun on improving medicines-manufacturing licensing.

🔬 Science — Medical Cannabis Consortium multi-clinic survey (n=6,282; 97.6% improvement); KCL IoPPN bidirectional CUD↔psychosis genetic map

• The Medical Cannabis Consortium published the first pooled UK multi-clinic survey on 22 May (5,128-patient mental-health sub-cohort): 97.6% symptom improvement, 92.3% better sleep, 93.5% better daily functioning, 88.3% rated it the most effective treatment tried.
• Context: 4m+ people in contact with NHS mental-health services in 2024/25; ≈30% of major-depression patients fail multiple treatment attempts (STAR*D); the consortium positions the data alongside the UKMCR and Project Twenty21 for considered prescribing in treatment-resistant patients.
• Mamedica’s Kretzschmar and Robson argued in Clinical Trials Arena why psychiatry needs better patient-outcome data (29 May), citing UKMCR case series showing significant 1/3/6-month improvements in anxiety, sleep and QoL and a two-year depression series showing sustained improvements.
  • They stress observational limits and the JAMA Internal Medicine warning that THC-predominant products carry substantial risk in bipolar and psychotic-spectrum populations.
• EMJ Reviews framed gender disparities in UK medical cannabis access at Cannabis Europa London (May 2026): market “tends to favour younger male users”; dosing varies across the menstrual cycle (Dr Natasha Mason, Maastricht); ENDOCAN-1 (CBD × endometriosis, NHS Lothian + NHS Grampian, 100-woman RCT) opens enrolment 1 June 2026.
• Prof Marta Di Forti and Dr Isabelle Austin-Zimmerman published the bidirectional Mendelian-randomisation analysis in Biological Psychiatry Global Open Science (13 May), combining schizophrenia + bipolar I GWAS; CUD→psychosis magnitude larger than psychosis→CUD; three distinct CUD→psychosis variant groups vs one in reverse.
  • A glutamate-system signal positions the analysis as “the groundwork for prediction models that identify those most at risk” — a risk-stratification scaffold for clinical prescribing.

🇨🇦 Canada — Health Canada opens industrial hemp consultation as cannabis farm receipts grow +16.9% to C$2.56bn

🔭 On the radar: Health Canada Industrial Hemp Regulations NOI consultation closes 30 June (six reform areas including 0.3% THC threshold amendment). Saskatchewan On-Reserve Cannabis Refund Program (Bill 50) effective 1 July. Aurora Q4/FY26 investor call 11 June; Simply Solventless CCAA filing target 18 June.

🏛️ Regulation — Health Canada opens industrial hemp NOI (45-day, 6 reform areas); Ontario extends retail to 7 am

• Health Canada published a Notice of Intent on 15 May 2026 opening a 45-day consultation (16 May → 30 June) on six Industrial Hemp Regulations reform areas; no draft regulation yet; CBD extraction remains under the Cannabis Act and out of scope.
  • MMJDaily maps the six reform areas in detail: licence cuts, removal of the import/export permit layer, reduced reporting, an overhaul of the List of Approved Cultivars (LOAC), easier THC testing and the proposed 0.3% threshold amendment.
  • USDA FAS GAIN attaché report CA2026-0011 (filed 22 May 2026) confirms 16 May → 30 Jun 2026 window from a US trade-policy lens, flagging US–Canada hemp trade implications.
• Health Canada published Section 244 product-notice guidance codifying SOR/2025-43: 60-day pre-sale notice for edibles, extracts and topicals via the Cannabis Tracking and Licensing System; 2-year record retention; 10 MB bundle cap; no fee; dried cannabis excluded.
• Ontario AGCO extended cannabis retail hours to a 7 am opening under Regulation 468/18 effective 1 May 2026, aligning with liquor-store hours; delivery hours unchanged (9 am–11 pm); 19+ age limit unchanged; curbside pick-up from 7 am enabled.
• PEI consults on raising cannabis age of access from 19 to 21 (brain-development and tobacco-parity grounds; consultation stage, no legislative vehicle); Saskatchewan launches On-Reserve Cannabis Refund Program under Bill 50 effective 1 July 2026, returning 50% of the province’s 75% federal excise share to qualifying First Nations.
  • PEI cites brain development to age 25 and parity with the existing 21-year tobacco age; provincial cannabis revenue C$26.4 m (FY2024-25, +6% YoY) with net income –19% to C$3 m; consultation stage, no legislative vehicle yet.
  • Saskatchewan’s Bill 50 (2026-27 budget, Minister Jim Reiter) carries an estimated cost of C$120,000 in 2026-27 with two of the province’s 204 on-reserve retailers currently qualifying; C$153.6 m in cannabis excise has been collected by the province between October 2018 and August 2025.

💼 Market — Farm receipts +16.9% to C$2.56bn; LP results confirm international-led growth

• 2025 Canadian market: farm cannabis receipts +16.9% to C$2.56bn (largest increase since 2020); recreational sales C$5.5bn (+6.1%); government revenue C$2.5bn (+11.5%); inhaled extracts 31.1% of sales; C$167 per legal-age adult (Yukon C$384, Quebec C$105).
  • CRB Monitor Q1 2026: active licences flat at 5,807; retail dispensaries +1% to 4,176; cultivation –2% to 889; applications in review –13% YoY, –76% over 2 years.
  • StatsCan March 2026 retail C$471.4m (+6.2% YoY); YTD 2026 C$1.389bn (+7.7%); Ontario +4%, BC +25%, Alberta –3%, Quebec +2% YoY. BC outsells Alberta for the first time (BC C$82m vs AB C$73m in Feb 2026). BCLDB Q4 direct-delivery +643% YoY to C$17.75m (12.4% of wholesale); 485 of 920 active federal licences now micro-producer.
  • OCS By The Numbers 2025: provincial 2025 retail C$2.28bn (+3.5%), 441M g (+5.6%) across 1,780 stores; vapes +14%, infused pre-rolls +12%; average wholesale C$3.75/g dried flower.
• Aurora Q3 FY2026 net revenue C$94.2m, medical +12% YoY, C$154m cash debt-free; FY26 guidance C$269–281m global medical revenue; Cronos Q1 international ex-Israel +97%, US$822m cash; Village Farms Q1 cannabis exports +171% YoY to ~US$15m led by Germany.
  • Organigram Q2 FY26 net revenue C$59.8m (–9% YoY), adj. EBITDA C$0.9m; Auxly Q1 C$39.8m (+22%) at 55% gross margin; Decibel Q1 C$29.8m (+41%, intl ×3 to C$9.6m); Rubicon Organics C$13.7m (+11%) with C$0.6m EBITDA loss.
  • Cronos Group Q1 2026 net revenue US$45.2 m (+40% YoY) with net income US$15.7 m (+103%), Israel revenue +53% and international ex-Israel +97%; cash US$822 m; a US$50 m share buyback launched; Spinach #1 in Canadian vapes at 9.8% share and #1 in edibles at 20.8% share.
  • Village Farms Q1 2026 cannabis-segment exports +171% YoY to roughly US$15 m led by Germany; consolidated net sales US$50.2 m (+27%); adjusted EBITDA US$10.2 m (20.5% margin); fourth consecutive quarter of positive net income; the Dutch Leli Holland wietexperiment unit prints +448% Q1 revenue with a €26 m Groningen expansion targeting ~10 t/year.
    • Altman Z”-score snapshot: only Cronos safe (>2); Cannara and Village Farms mid-range; SNDL, Decibel, Aurora, Canopy distressed (<1); Simply Solventless targets 18 June 2026 filing under CTMO extension (ANC, CannMart and Massive Hash Factory CCAA proceedings).
• Herbal Dispatch secured EU-GMP processing in Portugal (298 kg to Germany in Jan, permit time 6 weeks→7 business days); Rubicon Organics secured GACP certification at Cascadia (4,500 kg/year, +40%); Organigram frames Germany’s ~€2bn medical market as potentially doubling within 5 years.
  • Tilray Medical presented on the Evidence First panel (20+ markets, 40+ brands); post-Schedule III US re-entry thesis cites €100m European medical + US$50m Canadian sales as the capture base.
  • Canopy Growth / Spectrum Therapeutics extend Canadian medical depth with five new or extended Spectrum SKUs including 30- and 90-pack softgels and a higher-dose Daily Relief 30-pack.
• Cannara Biotech closes its acquisition of Medican Organic for C$2.8 m, completing the 2021 Valleyfield purchase; combined facility footprint 1.6 M sq ft; CFO Sosiak appointed COO on 23 April 2026.
• SNDL cancels its C$32.2 m purchase of 27 Ontario stores from 1CM citing regulatory delay (C$250 k termination fee); SNDL redirects capital to a C$100 m Share Repurchase Programme with 5.5 M shares repurchased for ~C$11.1 m.
• Go Brands‘ Lite Label range lifts average transaction value by C$6.44 (58% of consumers seek light cannabis); federal promotional rules sideline brands from the 2026 World Cup (350k+ tourists); Kanesatake’s 35–50 unlicensed Route 344 shops generate revenues ~4× the Mohawk Council’s annual budget.

🔬 Science — Canadian-led preprint maps 53 trichome regulator genes in Cannabis sativa

• Canadian-led bioRxiv preprint (29 May 2026): 53 candidate trichome regulator genes in Cannabis sativa; CsTT8, CsMYC1/GL3, CsGL2, CsYABBY4 and CsMIXTA-like1 flagged as glandular-trichome drivers. Companion multi-omics paper, MDPI Plants (25 May): stalk-zone roles in cannabinoid storage and secretion.

🇦🇺 Australia — TGA, RACGP and Federal Court converge on online prescribing channel (≈350,000 patients, >99% products off ARTG) in May 2026

🔭 On the radar: Federal Court of Victoria hearing against Montu/Alternaleaf begins 22 October 2026 (7 sitting days). Minns government to introduce NSW driving-reform legislation in the next sitting week. LGP–Cannatrek merger implements June 2026; Bioxyne GM 19 June, post-consolidation trading as BLS Pharmaceuticals from 24 June. Avecho insomnia Phase III interim readout due late June.

🏛️ Regulation — TGA tightens compounded-medicines penalties (A$1.65M / A$16.5M); RACGP rejects telehealth-only prescribing; Federal Court schedules Montu/Alternaleaf hearing

• RACGP declared questionnaire-only prescribing “unsafe and not supported” (12 May): requires real-time consultation for any prescription. The Federal Court of Victoria set a 7-day hearing from 22 October 2026 against Montu Group, Alternaleaf and founder Christopher Strauch (18 May).
  • CHOICE documented a 3.5-minute Alternaleaf doctor consult (19 May); AHPRA: 80 practitioners sanctioned since 2019; half of 54 reviewed clinic websites breaching guidelines; 25% of patients globally meet cannabis-use-disorder criteria.
  • Cannatrek reached an in-principle TGA agreement (11 May) on historical advertising breaches; civil penalty sized within LGP’s merger economics with ~A$6.5M additional capital contribution at completion.
• TGA compounded medicines guidance (14 May): civil penalties up to A$1.65M individual / A$16.5M corporate per breach; medicinal cannabis explicitly listed as higher-risk.
• Queensland — Health Minister Tim Nicholls formally rejected e-petition 4319-25 (5,283 signatures, 25 May); Crisafulli government reaffirmed zero-tolerance roadside/workplace THC testing despite tens of thousands of QLD patients affected.
• NSW — independent MP Alex Greenwich withdrew the Road Transport Amendment Bill on 19 May; Minns government signalled its own driving-reform legislation in the following sitting week; >100,000 NSW patients affected.
  • Victoria MLC Rachel Payne secured Legislative Council majority (13 May) noting Victoria Police’s September 2024 cannabis-cautioning policy expansion remains inconsistently applied across police, legal stakeholders and the community.
• MCCA unveiled its 7-member inaugural board on 8 May: Lucy Haslam (patient advocate), Ean Alexander/Phoebe Macleod/Sharon Bentley (industry), Dr Priya Ayyar/Nicholas Ravenswood (healthcare), Geoff Bloom (independent); Bloom elected inaugural chair 20 May. CCA and ANZCCP confirmed merger nears completion (19 May); combined ANZCCM debuts at ANZCCP annual conference 29–31 May.
  • Australian Industrial Hemp Alliance argued the ODC’s restrictive treaty interpretation caps domestic innovation and leaves Australia out of step with major hemp markets (7 May). NSW hemp leaders told the Senate RRAT inquiry (Canberra, 15 May) that entanglement with medicinal-cannabis rules plus state-by-state inconsistency raises legal costs and limits scale.

💼 Market — LGP–Cannatrek merger cleared 26 May; LGP FY26 Europe +137% overtakes Australia at Q4 run-rate

• April SAS-B: 18,740 scripts; pastilles at ~33% of approvals — highest share on record. Mood State Medical ambulatory heated nebuliser (ARTG ID 526764) is the first vape device admitted under the revised TGA framework; most cannabis products remain supplied via SAS-B and Authorised Prescriber unapproved-product pathways.
• LGP FY26 revenue A$42.43M (+15.2% YoY), A$1.41M net loss (FY25: +A$3.32M profit); Europe +137% to ~A$16M; Australian revenue –14% to A$26.4M; Europe overtook Australia at the Q4 FY26 run-rate. Federal Court approved the LGP–Cannatrek scheme of arrangement (26 May); formal implementation June 2026.
  • Management named Europe “primary growth driver” (Germany core); flower products A$30.5M (+31.5%).
• Bioxyne announced 1-for-10 share consolidation (21 May; GM 19 June); proposed name change to BLS Pharmaceuticals Limited; H1 FY26 revenue A$31.3M / EBITDA A$8.3M; FY26 guidance A$65–75M revenue, A$16.5–19M EBITDA.
  • First Costa Rica supply agreement signed with Remidose LATAM: 3 Dr Watson® flower SKUs; first shipment before 30 June; invoice >A$500K; future pastille supply to Costa Rica and Panama scoped.
• Cannaponics Limited cleared A$1.215M minimum from 579 investors on OnMarket (13 May); targeting A$1.5M–A$5M to fund commercial-scale cultivation and GMP completion on 165-acre WA site (A$38M invested to date, A$2M government grant, 4MW solar farm approved).
• Cannim Group creditors approved formation of committees (6 May) for Olvera Advisors’ litigation-funding deal for >A$13M recovery claims including alleged insolvent trading, uncommercial transactions and unfair preferences.

🔬 Science — TGA AE retrospective (n=614; psychiatric 30.6%); Sydney CBD RCT (~14% vs 6.5% placebo); Griffith fibromyalgia pilot (n=24, 70% ≥30% reduction)

• Australian & New Zealand Journal of Psychiatry TGA voluntary AE retrospective (3 May; n=614 cases / 1,124 AEs, Jul 2022–May 2025): psychiatric disorders 30.6% (n=344), nervous-system 17.9%, gastrointestinal 14.3%; 14 cases involved suicidal ideation or attempts; Category-5 (CBD <2%, THC up to 88%) products 54.1% of cases; 86% submitted by health professionals.
• University of Sydney reported ~14% pain reduction with CBD vs 6.5% placebo over 6 weeks in 40 adults with chronic neuropathic pain (spinal cord injury cohort); CBD dose titrated 200→800 mg/day; 78% of placebo participants correctly guessed allocation (potential unblinding).
• Griffith University pilot RCT (n=24): 70% ≥30% pain reduction post-titration vs 20% placebo; 40% clinically-meaningful FIQR improvement vs 10% placebo; 91.7% retention, ≥90% adherence; ACTRN12623000345684.
• Pharmacy Daily updated the EndoCann program at NICM HRI / Western Sydney University: three-arm RCT (balanced THC:CBD 10mg/mL, CBD-only, placebo) titrated to 20mg THC/day; women with endometriosis-related pelvic pain; 26-week design; ANZCTR 12624000328572.
• Avecho Biotechnology completed interim-analysis treatment phase for TPM-enhanced CBD soft-gel insomnia Phase III (n=244: 150mg, 75mg and placebo arms); interim results due late June 2026; Sandoz 2025 Australia licence (US$3M upfront + up to US$16M milestones + 14–19% royalties).
• Nexalis Therapeutics (formerly InhaleRx) completed Phase 1 dosing for IRX-616a (18 May): inhaled CBD for acute panic/anxiety episodes; no serious adverse events; moving to Phase 2 planning.
• Cannabiz reported pain white paper delay (26 May) from The Health Collective — collaboration between OnTracka and NICM researchers Mike Armour and Chad Walkaden.

🇫🇷 France — DGAL ends administrative tolerance for CBD foods from 15 May; ≈2,000 boutiques and >1,500 farms exposed

🔭 On the radar: Conseil d’État référé filed early June (Uivec/AFPC/FNSEA/Confédération paysanne); ministérial meeting imminent. Rist medical-cannabis decree targets late 2026; HAS evaluation and reimbursement contingent on outcome.

🏛️ Regulation — DGAL ends CBD food tolerance 15 May; Conseil d’État référé filed; 92% poll backs medical authorisation

• DGAL ended administrative tolerance for CBD foods effective 15 May: CBD herbal teas, oils, lozenges and chocolates off the market; >2,000 stores affected; ~40% of specialist-shop turnover at risk. Change is administrative (maximalist application of EU Novel Food via 2026 control plan) — no new statute bans CBD foods.
  • Uivec, AFPC, FNSEA and Confédération paysanne filing a Conseil d’État référé early June “barring a last-minute reversal”; joint statement: plan “implemented without consultation with the sector or any adaptation period”; ministérial meeting imminent.
  • UPCBD (Paul Maclean): “kills an agricultural sector and risks destroying more than 2,000 specialist shops”; central legal argument: DGAL plan conflates plant-extracted CBD with synthetic CBD from third countries; examining legal remedies.
  • Confédération paysanne open letter to Ministry: >1,500 farms in the supply chain; previous informal thresholds (50 mg/day daily intake, 20% max oil concentration, 1 µg/kg ARfD on THC) collapse under the new posture. SPC, UIVEC, AFPC and UPCBD demand suspension and refocus on synthetic narcotic cannabinoids.
  • EFSA February 2026 update: provisional safe intake 0.0275 mg/kg/day (≈2 mg/day for a 70 kg adult) for isolated CBD ≥98% under strict conditions. Novel Food dossiers: €60,000+ each; 200 filed, 0 approved. CBD market: €600m in 2025, projected €1bn in 2026; expected producer revenue loss 30–40%.
• 92% of French respondents back authorising medical cannabis (Apaiser/Norstat; 1,004 respondents, 13–14 April 2026): 72% want broad authorisation across all scientifically-evidenced indications; 82% view limited French access as problematic vs Germany, Netherlands, Italy and Luxembourg. Up from 70% (IFOP 2022) and 82% (2018).
  • ANSM-led 2021–2024 experimentation: ≈3,000 refractory patients (epilepsy, neuropathic pain, chemotherapy side-effects, palliative care); no new patients enrolled since March 2024; ≈750 remain under successive extensions.
  • Minister Stéphanie Rist’s draft decree (February 2026): HAS to evaluate cannabis-based medicines for authorisation and reimbursement; dried flowers excluded — only standardised pharmaceutical formats (oils, capsules, sprays); France notified European Commission March 2025; targets finalisation late 2026.
• JIRS Paris dismantled a California-to-EU cannabis trafficking network: 430 kg seized across 4 air-freight shipments (30 kg hidden in an arcade console, others in flat-pack furniture and fitness equipment); 21 shipments estimated since June 2025; 5 indicted (4 in pre-trial detention).
  • Similar parcels intercepted in Luxembourg, Germany and Switzerland. 2024 US legal production: US$38.5bn; 0.5 t US-origin cannabis seized in France in 2024; 3.7 t seized at Antwerp in June 2025.

💼 Market — France leads EU industrial-hemp exports at 47,765 t (72% share); PGP Farmer opens Dordogne production

• France exported 47,765 t of industrial hemp raw materials in 2024–25 (up from 415 t in 2021–22), 72% to EU; 22,600 ha across ≈1,550 growers in 2024 (doubled in a decade); 140,000 t processed straw + 11,000 t seed; 7 processing plants mainly in northern France. FranceAgriMer ranks France world’s second-largest industrial hemp producer after China.
  • Grand Est leads at 11,752 ha (Aube and Marne); organic hemp: <100 ha (2015) → ≈1,500 ha (2022). Fibre delivers 50% of value despite 28% of product weight; hurd is the largest weight share; downstream: hempseed (food, oils, protein), hurd (bedding, construction, mulch), fibre (paper, insulation, composites, textiles).
  • InterChanvre formally excluded flowers from its scope from January 2024, grouping FNPC, UTC, Terres Inovia, HEMP’it, FRD and INRAE under a unified industrial hemp policy.
• PGP Farmer launched a 30-variety Dordogne phenotyping trial in partnership with Dutch platform Innexo BV; led by CSO Frédéric Lota (Doctor of Plant Biology, 15 years applied R&D). 9-hectare site; long-term capacity projected 30 tonnes; €3m funding round closed February 2026; contributed to joint HAS dossier for full French medical rollout. Only French operator in raw pharmaceutical materials (MPUP) ahead of the reimbursement window.
• GoldBar420 voluntarily halved 2026 production to 700 kg (vs 2.6 t prior year) to build a parallel beldia THC stream targeting the medical pharmacy channel. 11 selections maintained for ≈350 partner boutiques; lots certified free of heavy metals, pesticides and insecticides; terpene families: limonene, caryophyllene, humulene, bisabolol, myrcene.
• Organigram cites France as a next disciplined expansion step following Sanity Group acquisition (Sanity revenue €9m → ≈€60m, 2023–2025, positive EBITDA); CEO Yamanaka names France, Spain, Portugal and Netherlands as next wave after Germany/Poland/UK.

🔬 Science — GoldBar420: altitude UV cultivation drives resin complexity indoor production cannot replicate

• GoldBar420 documents that altitude UV cultivation drives trichome complexity that indoor/artificial-light cultivation cannot match: thinner air, stronger sun and sharper temperature swings trigger physiological adaptation producing denser, more aromatic and chemically complex resins. Reconstructed resins built since 2020 lack the plant-origin chemical diversity.

🇮🇱 Israel — MoH Bodenheimer committee recommends 3-year smoked-flower phase-out and HMO transfer; Cronos Israel +53% YoY

🔭 On the radar: DG Bar Siman-Tov sign-off on Bodenheimer recommendations pending; implementation pathway (ministerial regulation vs. Knesset legislation) unspecified. Coalition approval window under six months ahead of elections.

🏛️ Regulation — Bodenheimer committee recommends 3-year smoked-flower phase-out, HMO transfer, tighter PTSD prescribing (not yet binding)

• Calcalist 3 May: MoH Bodenheimer committee submits 46-page report to DG Moshe Bar Siman-Tov; recommends 3-year phase-out of smoked medical cannabis, full HMO transfer within ~12 months, tighter PTSD prescribing. Recommendations not yet binding; DG sign-off + political approval required.
  • New patients transition immediately to extracts, oils or precision inhalers; grace period for patients over 75 and terminally ill. Market context: licences ~140,000; 87% smokers; 98% smokable products; 27% of Israelis 15+ report high-THC use (New Frontier Data 2025, world’s highest).
  • Committee grounds phase-out in international precedent: FDA has approved no smokable preparation; Canada, Germany and Australia rely on extractions, oils or inhalers.
• HMO transfer: diagnosis, approval, dispensing and monitoring centralise within the health fund. HMOs given ~12 months to prepare. Monthly renewals up to 6 months; beyond 6 months requires in-person reassessment + confirming-physician sign-off.
• PTSD prescribing tightened: addiction-risk questionnaire at treatment onset; “red flag” and discontinuation protocols; psychotherapy mandatory; dose and THC-level reductions required. Consumption projected to double absent intervention; committee finding: long-term harm proven, PTSD benefit insufficiently proven.

💼 Market — Cronos Israel +53% YoY; PEACE NATURALS #1 for 9th consecutive quarter; IM Cannabis C$2.5m net loss

• Cronos Group Q1 2026 earnings: Cronos Israel net revenue +53% YoY; PEACE NATURALS #1 cannabis brand 9th consecutive quarter. Consolidated: net revenue US$45.2m (+40% YoY), gross profit US$19.2m (42% margin), net income US$15.7m (+103%), adj. EBITDA ~US$5.1m (+122%); US$822m cash, no debt. Spinach® reached #1 Canadian vape market share Q1. US$50m share buy-back renewed 14 May 2026.
• IM Cannabis Q1 2026: revenue C$8.7m, gross profit C$1.4m, net loss C$2.5m (C$0.38/share); G&A −22% YoY. Two convertible notes: US$250k (6 April) + US$300k (7 May); combined ~1.40M warrant coverage. Platform: Israel (retail pharmacies + online) and Germany (Adjupharm GmbH).

🔬 Science — Aviram et al. PTSD scoping review: 1 of 7 RCTs efficacious (n=3,598); RCK F1 hybrid seeds ~17.5× yield

• Aviram et al., Journal of Cannabis Research 29 May (PRISMA-ScR; 1,474 titles, 26 studies, n=3,598): only 1 of 7 RCTs statistically efficacious for PTSD — nabilone vs. placebo for nightmares. 2 RCTs of inhaled/oral cannabis: no superiority over placebo. 2 RCTs of oral THC during fear-extinction: neurobiological changes, no clinical symptom improvement. 2 RCTs of acute oral CBD: minimal, transient modulation. Affiliations: Ariel University, Syqe Medical, Maale Hacarmel, Rambam, ICAR/Technion Rappaport.
• Ynet 13 May: RCK (Kibbutz Ruhama) reports ~17.5× output increase and ~70% reduction in production waste with F1 hybrid cannabis seeds; operated through October 7 war period at ~30% workforce availability. One of four firms worldwide developing F1 hybrid cannabis seed technology. MoA context: cultivation footprint ~350 dunam across 33 licensed growers.

🇧🇷 Brazil — ANVISA replaces RDC 327/2019 with four-resolution package (RDC 1.012–1.015/2026) effective 4 May; first-ever domestic cultivation authorised

🔭 On the radar: First cultivation licences under RDC 1.013/2026 and first export contracts expected June–August 2026 ahead of the 4 August compliance deadline. RDC 1.012/2026 research-track authorisations will test whether the UFMT/CEIFMT model scales to other federal universities. Court-supported activities comply by 5 August 2027.

🏛️ Regulation — ANVISA replaces RDC 327/2019 (effective 4 May): domestic cultivation authorised, 5 routes of administration, pharmacy dispensing; 13 May follow-up simplifies low-THC prescribing

• ANVISA four-resolution package RDC 1.012–1.015/2026 (effective 4 May): ends RDC 327/2019 regime per STJ IAC 16 mandate; first-ever domestic cultivation authorised (research + ≤0.3% THC medical/export); 5 routes of administration; pharmacy and compounding dispensing; THC access widened from terminal/palliative to all severe debilitating diseases. 13 May follow-up moves ≤0.2% products to Special Control Prescription and unlocks export cultivation. Compliance: 4 August 2026 (cultivation) / 5 August 2027 (marketing/manufacture).
• Chambers & Partners and Lexology framed the four-RDC package as the operational delivery of the STJ’s IAC 16 ruling: RDC 1.012/2026 governs research-track cultivation with no THC ceiling for ANVISA-accredited legal entities, RDC 1.013/2026 governs ≤0.3% THC medical-purpose cultivation, RDC 1.014/2026 launches the patient-association Regulatory Sandbox already in force, and RDC 1.015/2026 replaces RDC 327/2019 for marketing authorisation; court-authorised growers operating under existing judicial orders have until 5 August 2027 to align.
• g1 / Globo reported the resolution on 13 May: cannabis products with THC ≤0.2% move from the yellow Notification of Prescription A (used for narcotics and stricter-controlled medications) to the Special Control Prescription, a simpler form already used for various controlled medicines; black-striped packaging already in circulation may continue to be sold until expiry provided the patient holds the matching Special Control Prescription.
  • The same 13 May resolution authorises domestic cultivation of Cannabis sativa L. with THC ≤0.3% exclusively for export, conditional on documented export contracts (purchase, sale and distribution); the rule also updates import and export procedures to align with ANVISA’s existing sanitary regulations and is built on the Superior Court of Justice‘s criteria for low-THC varieties.

💼 Market — Legal patient base ≈672,000 (ANVISA, May 2025) on German-tier trajectory; import-dependent supply meets domestic cultivation tracks from 4 Aug 2026

• Brazil legal patient base: ~672,000 (ANVISA, May 2025); materially higher by November 2025; population 221 million puts Brazil on a German-tier trajectory (700k–900k active patients). Supply near-100% import-dependent; domestic cultivation tracks open 4 August 2026 under RDC 1.013.

🔬 Science — UFMT CEIFMT: first state-level research hub under RDC 1.012 cultivation track

• UFMT CEIFMT (Cuiabá campus) is Brazil’s first institutionally structured cannabis research hub: 2024 R&D agreement between UFMT, Uniselva Foundation and BYONGE; controlled cultivation, extraction and QC facilities under construction to pharmaceutical-grade standards; ANVISA authorisation track under RDC 1.012/2026 (no THC ceiling for accredited entities); SisGen biodiversity compliance. Sechat, 14 May.
• BYONGE executive director Carlos Eduardo Araújo: regulatory authorisation sits with UFMT under ANVISA. Workstreams: chemotypes under controlled stress (Mato Grosso), phytochemical stability, biomass yield, GACP protocols; targets protected cultivars, patentable processes, international breeding partnerships.
  • Scholarships announced via university notices (undergraduate, master’s, doctorate); SisGen biodiversity-legislation compliance in place.

🇳🇱 Netherlands — Leli Holland Q1 revenue +448% YoY confirms the wietexperiment at audited scale (≈10,000 kg/year Groningen design capacity)

🔭 On the radar: Village Farms / Leli Holland Phase II Groningen site reaches full ~10,000 kg/year design capacity by end-2026; 4-year payback target on €26m Dutch investment. Becanex PIEX Bedrocan® 70%-THC raw extract opens to German pharmacy orders summer 2026. Innexo BV GreenTech Edition Acceleration Day 8 June 2026 (~100 industry decision-makers).

🏛️ Regulation — Trimbos and BCD reaffirm post-2020 protocols after probable MDMB-IPINACA detection in Amsterdam coffeeshop hash sample

• Probable MDMB-IPINACA (≈0.63%) detected in blue-coloured “Blue Magic” melt hash at an Amsterdam coffeeshop: reported by cannabisindustrie.nl on 18 May; accredited Slovenian lab Spectral Fingerprints identified the compound; sample profile 86.12% CBD / 0.14% THC consistent with CBD extract spiked to mimic THC. GC-MS isolated a divergent peak (new indazole-type molecule, isopentyl derivative of MDMB-PINACA, Schedule I under Opiumwet); identification is probabilistic — no NMR confirmation; specific isopentyl variant not in published EUDA early-warning reports.
  • Surfaced late April 2026 via two r/AmsterdamEnts Reddit posts (bubblegum smell, sweet vape-juice taste, burning throat); Purpl PRO distributor Tradelinc BV routed sample to lab analysis; coffeeshop pulled the product; notification filed with Trimbos-instituut.
  • Anomalous CBD/THC ratios flagged in other coffeeshop hash samples: La Mousse (4.32% THC / 10.51% CBD), Libanon (2.40% THC / 13.85% CBD), Piatella (5.09% THC / 44.39% CBD) — without additional synthetic-cannabinoid testing.
• coffeeshopbond.nl reaffirmed post-2020 protocols on 25 May after consulting Trimbos: lab result cannot be verified (lab unknown to Trimbos; substance name not in international chemical databases); no current indications of large-scale synthetic-cannabinoid contamination; protocols established after the autumn 2020 DIMS Red Alert for MDMB-4en-PINACA remain in force.
  • Operators stay alert to abnormal consumer complaints (severe anxiety, paranoia, dizziness, palpitations) and refer to drugs-test.nl / dims@trimbos.nl for reactive testing; cannabis cannot be preventively tested before use under current Dutch drug-checking rules.

💼 Market — Leli Holland +448% Q1; Bedrocan/Becanex PIEX 70% THC opens to German pharmacies; Enschede fibre-hemp pilot

• Leli Holland (Village Farms) Q1 2026: revenue +448% YoY; Groningen Westpoort site opened 24 April with 10 grow rooms / ~1,400 plants under LED lighting; ~10,000 kg/year design capacity; total Netherlands investment €26m, 4-year payback target. (cannabisindustrie.nl, 14 May)
  • Consolidated Village Farms Q1: revenue US$50.2m (+27% YoY); cannabis gross margin 43%; Adjusted EBITDA US$9.9m (+118% YoY); international export sales US$14.6m (+171% YoY); fourth consecutive quarter of positive net income.
• Bedrocan / Becanex partnership announced 19 May: Becanex PIEX Bedrocan® 70% THC raw extract preserving cannabinoid and terpene fingerprint; EU-GMP production in Netherlands and Denmark; designed for oral solutions, capsules, suppositories, topicals and inhalation; pharmacy orders open from summer 2026; Berlin §13(1) AMG manufacturing licence and GMP certificate. Germany is the first launch market.
• PGP Farmer 30-variety Dordogne phenotyping trial in partnership with Innexo BV (Dutch applied-research platform licensed to conduct cannabis trials); led by CSO Frédéric Lota; 9-hectare site, projected 30 t capacity; €3m funding round closed February 2026. European medical-cannabis demand growing >20%/year; ~75% of EU flower imported from outside Europe.
• Organigram CEO James Yamanaka names Netherlands as next disciplined expansion step after Germany/Poland/UK (post-Sanity Group acquisition: Sanity revenue €9m (2023) → ~€60m (2025), positive EBITDA); Germany medical market ≈€2bn with a more-than-double-in-five-years projection.
• Enschede fibre-hemp pilot: ~3.5 hectares of fibre hemp sown in partnership with Twentse Bouwboeren and Technology Base; municipality (Wethouder Niels van den Berg) positions pilot as buyer-side push toward 2030 50% iron-and-gas reduction target; harvest residues assessed for energy recovery. Former dairy farmer Gerard Seijger (De Lutte) on his second harvest; hemp insulation already produced.

🔬 Science — Innexo Acceleration Day positions genetic standardisation as pharmaceutical-grade prerequisite; Dutch addiction care 2025: ~11,000 cannabis treatments, 40% of under-25 caseload

• Innexo GreenTech Edition Acceleration Day (8 June 2026, Netherlands; ~100 decision-makers, ~50 representatives from 30 licensed producers): previewed by MMJDaily on 26 May. Programme: advanced seed sorting and spectral fingerprinting, phenotyping essentials, polyploid plants, epigenetics, mutagenesis and space breeding; trial updates from Faven and Atami; expert panel moderated by Xavier Gaya (Avitas Global); closing keynote by Jorge Cervantes.
• IVZ/LADIS Kerncijfers Verslavingszorg 2016–2025 reported by cannabisindustrie.nl on 29 May: ~68,000 treated in Dutch addiction care in 2025; ~11,000 treated for cannabis problems (primary); >6,000 cannabis as secondary (most often paired with primary alcohol); 40% of all under-25 caseload had a cannabis problem; average treatment age rose from 30 (2016) to 32 (2025).
  • Comparator caseload: online-gambling treatment +13% YoY to >3,100 cases; 3-MMC treatments 709→946; ketamine treatments 606→714; alcohol remains dominant at 43% of all treatments. IVZ does not disaggregate cannabis-with-tobacco versus cannabis-alone (Trimbos 2019: 90.7% Dutch cannabis consumption involves tobacco co-use).

🇪🇸 Spain — Tribunal Supremo STS 301/2026 brings CBD-flower retail inside art. 368 CP perimeter at THC 0.3–0.7%

🔭 On the radar: TC appeal of STS 301/2026 pending (Lawyer Sierra + BrotSanBert); doctrine consolidates only on a second confirming Sala Penal casación ruling — open contestation window through H2 2026. ProfesorCBD/Iribarne medical-cannabis delivery device in Phase 1 development (RD 903/2025); EU certification roadmap 3–4 years.

🏛️ Regulation — STS 301/2026 criminalises CBD-flower retail at 0.3–0.7% THC, exposing ≈700 specialist retailers and a €136m vertical

• STS 301/2026 (Sala Penal, 23 April 2026; ponente Pablo Llarena Conde) overturns AP Barcelona’s absolution and restores the conviction against Sensitive SBD / Hemp Lovers: 2,368.96 g seized (THC 0.3–0.7%, CBD up to 13.9%), penalty 1 year 2 months prison + €8,000 fine. Intervened December 2020 by Vigilancia Aduanera at UPS Barcelona Zona Franca on two Paris-bound parcels.
  • Doctrinal shift: the TS rejects the UNODC THC+CBN/CBD index as a criminal yardstick — it is un instrumento orientativo, not part of art. 368 CP. The 0.2% THC administrative threshold no longer shields retail formats; criminal exposure now turns on detectable THC + ready-to-consume packaging + commercial destination, alongside the 10 mg psychoactive dose anchor.
    • Francisco Azorín Abogados (25 May) challenges on three grounds: (i) the 10 mg dose threshold derives from a non-published INTCF report (nº 12691/03, 2001/2003) based on synthetic oral dronabinol, not full-spectrum cannabis, and pre-dates UNODC ST/NAR/40 (2010); (ii) the density-of-norm objection the TS applies to UNODC manuals applies equally to INTCF reports; (iii) tension with TJUE Kanavape (C-663/18), JIFE Ref. E/INCB/NAR/C.L.20/2024, STS 205/2020, STS 855/2021, and STSJ Madrid 158/2025.
      • TC appeal: the CBD industry will challenge via Lawyer Sierra and BrotSanBert; STS 301/2026 is not yet jurisprudencia consolidada — a second confirming ruling is required before doctrine is settled.
  • Channel exposure: ≈700 CBD specialist retail points + ≈600 grow-shops; CBD vertical sized at €136m; ruling-era reference prices: €5/g, €1,800/kg.

💼 Market — ProfesorCBD secures Elkargi-backed funding for Spain’s first medical cannabis delivery device; genetics lane differentiates Spain from Portugal’s GMP hub model

• ProfesorCBD / Cannabioteacher (Borja Iribarne, Málaga) has secured financing — guaranteed by Elkargi (SGR) following an innovation-project certificate from BEAZ (Diputación Foral de Bizkaia).
  • To begin Phase 1 development of a device for precise, controlled administration of magistral medical cannabis formulations under RD 903/2025. Target: EU medical-device certification in 3–4 years; no market event before 2029.
• Structural constraint vs Portugal: Spain requires cultivation and GMP processing under one roof; Portugal allows separate GACP cultivation + GMP processing, lowering the entry barrier. Most Spanish exports historically went to the UK; Germany now leads, but Spain retains a more diversified export profile than Portugal (≈90% Germany-dependent).
  • Spain’s clearest differentiation: genetics sector — several Spanish breeding operators supply varieties into Portugal, Spain, and other European markets, independent of GMP infrastructure constraints.
  • Czechia and Malta emerging: Czechia has accelerated post-German legalisation, with hemp growers validating to GMP standard on Germany’s doorstep; in some early-2026 months Czechia exceeded Portugal in Canadian export value received. Malta draws from a diverse origin base (Israel, South Africa, Canada) and shows consistent growth in Canadian export data.
• Organigram CEO James Yamanaka (MJBizDaily, 21 May): Sanity Group revenue €9m (2023) → ≈€60m (2025), positive EBITDA post-acquisition; France, Spain, Portugal, Netherlands cited as next steps after Germany/Poland/UK. German medical market sized at ≈€2bn.

🔬 Science — Phase III “Spectrum” full-spectrum extract cuts a 7-year-old TSC2 patient’s seizures from up to 28/day to ≈3/month

• Karla, age 7, TSC2 mutation: enrolled ≈1 year 8 months in the Phase III “Spectrum” trial of a full-spectrum cannabis extract by Oils4Cure. Seizure frequency: up to 28/day → ≈3/month. Reported functional gains: mobility (reduced orthopaedic stroller reliance), speech, and cognition. (Telecinco / Informativos, Candela Hornero, 15 May.)

🇨🇭 Switzerland — Cannabis Products Act (CanPG) clears public consultation but returns to committee for revision

🔭 On the radar: SGK-N subcommittee CanPG revision underway; no public timetable for return to National Council. Züri Can pilot extended to October 2028. Parallel pilots: Lausanne (Cann-L), Bern, Basel, Biel, Vernier, Geneva and Lucerne.

🏛️ Regulation — Cannabis Products Act (CanPG) consultation closes with 162 submissions and a 10–1–15 cantonal split; the National Council’s health committee (SGK-N) refers the draft back to subcommittee (7 May)

• IG Hanf Schweiz consultation analysis: 162 submissions (128 organisations invited, 76 responded; 86 spontaneous). Cantons approve (10): SG, AI, BS, GE, GL, GR, NE, OW, SO, VD. Neutral (1): VS. Reject (15): AG, BE, BL, FR, LU, NW, SH, SZ, TG, UR, ZG, ZH, AR, JU, TI.
  • 18 cantons flag enforcement too complex/expensive and demand additional funding; 12 consider regulation premature pending pilot evaluation; 7 judge youth-protection measures insufficient.
  • SODK (cantonal social-affairs directors): tends approve, conditional on a dedicated consumption tax.
• Parties pro (4): GLP, Greens, SPS, FDP. Contra (4): The Centre, EVP, EDU, SVP.
• Commissions/umbrellas: EKKJ, EKSN, WEKO, SSV (cities) approve; SBV (farmers) neutral; SGV (SMEs) rejects. 28 of 33 addiction-and-prevention organisations approve. EKSN-commissioned international review rates draft “well-conceived, coherent and internationally groundbreaking.”
• Fachverband Sucht / SSAM joint release 5 May: Cann-L (Lausanne) interim qualitative read-out: majority of participants left illegal market; consumption declining; more users seeking medical advice; black-market revenues diverted to prevention and research.
• International CBC: confirms City of Zurich Züri Can extension to October 2028; Zurich, Basel and Bern pilots: regulated access does not increase consumption; strengthens public-health protection; improves user support.

🔬 Science — Züri Can first systematic health-outcome read-out: regulated access reduces problematic use, sleep disturbance and anxiety (3,100+ participants, 20 outlets)

• Stadt Zürich 2026: Züri Can 3,100+ adult participants across 20 outlets; regulated access linked to lower problematic use, sleep disturbance, anxiety and physical complaints; depression and chronic-health metrics stable. University of Zurich attributes improvements to harm-reduction measures: individual specialist counselling, THC limits and purchase limits.
• Limmattaler Zeitung 4 May (Lukas Elser): Schlieren cannabis breeder relocates into JED innovation centre — continued commercial Hemp/Science buildout parallel to federal reform.

🇮🇹 Italy — Courts send the hemp-flower ban to the Constitutional Court as the EU backs whole-plant hemp subsidies

🔭 On the radar: Corte Costituzionale ruling expected within ~12 months (consolidated Brindisi 2 Dec 2025 + Trani 28 Apr 2026 referrals; ~150 procedimenti queued). Decreto Florovivaismo schema 60-day parliamentary conversion window opens 25 May. EU CAP whole-plant eligibility moves to Commission + Council trilogues (~12+ months).

🏛️ Regulation — Courts refer the hemp-flower ban to the Constitutional Court; EU backs whole-plant subsidies; police summon medical-cannabis patients

• Trani ordinanza (28 April) (Barletta vending-machine case): 0.2–0.8% THC inflorescences found “non appare idonea ad alterare lo stato psicofisico”; drogante-efficacy threshold anchored at Law 242/2016 0.6% boundary — absence of offensività in concreto = no criminal offence.
  • Recent dissequestri: 530 kg returned by Procura di Imperia (11 April 2026); Sassari sequestro annulled (24 March 2026). Canapa Sativa Italia president Mattia Cusani: “Da gennaio i sequestri sono sostanzialmente fermi”; avvocato Giacomo Bulleri: dissequestri have outpaced the Oct–Dec 2025 seizure wave.
  • Sector footprint: ~22,000 FTEs, ~€1bn direct + ~€1bn indirect economic impact.
• Federcanapa (7 May): EU REGI Commission confirms inflorescences and resins as CAP-eligible plant parts; current EU THC ceiling at 0.3% (Cristina Guarda 0.5% amendment already approved by Parliament; Italy’s Law 242/2016 sets 0.6%); Fratelli d’Italia carve-out amendment defeated. Valentina Palmisano (M5S) leads the policy file. HempToday (15 May): hemp flowers classified as agricultural products eligible for marketing as an integral part of the plant; Commission + Council negotiations ~12+ months to final adoption.
• Federcanapa (25 May): Decreto Florovivaismo schema Article 1 comma 4 embeds the Decreto Sicurezza flower-as-narcotic framing inside an otherwise floricoltura/vivaismo decree. Federcanapa, Canapa Sativa Italia, EIHA, Confagricoltura and CIA target clause removal during parliamentary conversion.
• Il Fatto Quotidiano (28 May): Carabinieri summoned medical-cannabis patients as “persone informate dei fatti” across 6 cities — stage-III oncology, MS, epilepsy, anorexia and vulvodynia patients, prescribing doctors and veterinary cases. Denounced by Meglio Legale (Antonella Soldo) and WildSide Legal (Cathy La Torre).
  • Procedural pattern: signed depositions, no copy released to patient; WhatsApp and email screenshots requested; no concrete investigative grounds disclosed. Legal risks: GDPR/sensitive-health-data violations, discrimination relative to other psychotropic prescriptions.
• UCS + AIFA + Stabilimento Chimico Farmaceutico Militare di Firenze two-day workshop: new EU/Italian regulatory scenarios, GMP/GACP, authorisations and international reporting; Italy positioned as EU reference donor for candidate-country medical-cannabis frameworks; Albania’s Law 31/2024 set to track Italian norms.

💼 Market — Hemp acreage rebounds 51% to 513 ha in 2025, still below the 2019 peak of 907 ha

• Confagricoltura (5 May): Italian industrial-hemp cultivated area 513 ha in 2025 (+51% YoY vs 340 ha in 2024 / 298 ha in 2023); below 2019 peak of 907 ha. Legal uncertainty continues to constrain new investment ahead of Constitutional Court and CJEU outcomes.

🇬🇷 Greece — Draft bill bans hemp-flower retail (€100k fines, 5-yr prison)

🔭 On the radar: Parliamentary vote on hemp-flower retail ban pending OKE response. EU free-movement challenge expected if enacted as drafted. Industrial-grade hemp imports for domestic processing remain permitted.

🏛️ Regulation — Greek draft bill bans dried hemp-flower retail (€100k fines, 5-yr prison, 0.3% THC limit); the state’s Economic and Social Committee (OKE) warns it clashes with the EU’s Kanavape ruling

• Business of Cannabis 8 May (Ben Stevens): Greek draft bill bans dried hemp-flower retail; fines up to €100,000, 5-year prison, 0.3% THC limit, 500m school buffer; permits only industrial-grade imports for domestic processing. OKE (Economic and Social Committee) formally warns the ban contradicts EU jurisprudence (CJEU C-663/18 Kanavape) on free movement of hemp-derived products legally produced in another Member State.
  • Kanavape ruling (CJEU, 2020): Member States cannot prohibit marketing of CBD legally produced elsewhere unless backed by sufficient public-health scientific evidence. OKE suggests the Greek draft would struggle to meet this bar.
  • 0.3% THC ceiling aligns with prevailing EU agricultural-hemp threshold; the retail ban creates a structural tension (supply permitted, sale forbidden).

🔬 Science — MDPI Horticulturae trial (Greek team): 18 plants m⁻² + 10-day veg yields 1,091 g m⁻² with THC stable across treatments

• MDPI Horticulturae 12(5)/619 (Karnoutsos, Mallis, Sarrou, Koukovinos, Tsaliki, Karagiovanidis, Ganopoulos, Kalivas; Royal Queen Seeds-linked genetics): LED-grown cannabis planting-density × veg-duration trial under ~400 ppm CO₂ and ~400/800 µmol m⁻² s⁻¹ PPFD.
  • 18 plants m⁻² + 10-day veg: 1,091 g m⁻²; 10 plants m⁻² + 28-day veg: 1,009 g m⁻². Total THC stable across densities, durations and canopy positions.

🇩🇰 Denmark — Copenhagen Police’s largest-ever grey-market raid (600+ products, 2 life-threatening poisonings)

🔭 On the radar: OSA forensic-testing pipeline determines whether seized Sense Organics ApS stock is destroyed or returned as technically legal, shaping Denmark’s next <0.2% THC kiosk-threshold review (Fødevarestyrelsen, Erhvervsstyrelsen, Sundhedsstyrelsen). Becanex PIEX 70% THC raw extract (EU-GMP, Denmark + Netherlands supply) opens to German pharmacy orders summer 2026.

🏛️ Regulation — OSA executes largest-ever grey-market raid on Sense Organics ApS (28 April); H4CBD + synthetic EDMB-4en-Pinaca and MDMB-Pinaca in 4/19 samples; 2 life-threatening poisonings

• Københavns Politis Operative Specialafdeling (OSA) seized 22 moving boxes / 600+ grey-market cannabis products from Sense Organics ApS across 3 Copenhagen warehouses (Østerbro, Nørrebro, Vesterbro) on 28 April 2026 (reported 3 May). Forensic testing: H4CBD + synthetic EDMB-4en-Pinaca and MDMB-Pinaca in 4 of 19 samples; 2 consumers in life-threatening condition. Berlingske on-the-ground coverage (Bjørnager/Ladefoged, 3 May).
  • Products span flower, hash, oils, vapes, gummies, creams, chewing gum, THCA powder and unidentified liquids; Københavns Universitet forensic chemists described the volume as “completely unmanageable,” atypical for a narcotics case.
  • Two consumers in life-threatening condition: one man in his 50s unconscious for 4 days at Bispebjerg Hospital. Giftlinjen ovrlæge Dorte Fris Palmqvist confirms severe cases requiring respirators and organ-function support; attributes severity to synthetic/semi-synthetic compounds, not THCA.
  • Sense Organics ApS 2024 precedent: ~30 kg cannabis previously seized from same firm + 8 kg illegal hash/skunk; multimillion-DKK 2024 turnover; distributed via hundreds of independent kiosks nationwide plus an online shop.
• Synthetic cannabinoids EDMB-4en-Pinaca and MDMB-Pinaca already flagged by Sundhedsstyrelsen in February 2026 following a fatal poisoning in Jutland linked to puff-bars and e-cigarette liquids.
  • Grey market expanded across Copenhagen after the final closure of Pusher Street (Christiania) two years ago.
  • OSA forensic-testing outcome determines whether seized stock is destroyed or returned as technically legal — result shapes Denmark’s <0.2% THC threshold and kiosk-display rules (grey-market products currently sit more openly than tobacco, which must be hidden behind curtains).

💼 Market — Denmark #3 in Germany Q1 2026 imports (3,338 kg / 6.6%); Bedrocan / Becanex confirms Denmark as EU-GMP supply site for PIEX 70% THC extract

• BfArM Q1 2026: Germany imported 50,539 kg medical cannabis; Denmark supplied 3,338 kg (6.6%) — third behind Canada (26,753 kg / 53%) and Portugal (10,342 kg / 20%). Germany exported 1,526 kg; domestic German licence count: 3, two linked to Tilray/Aphria and Aurora. (StratCann, David Brown, 15 May)
• Bedrocan / Becanex partnership announced 19 May: BfArM-approved Becanex PIEX 70% THC raw extract preserving flower fingerprint; EU-GMP supply sites in the Netherlands and Denmark; orders open, technical dossiers on request; Berlin §13(1) AMG licence.

🔬 Science — Cambridge 23-year ecological study: THC resin potency 8.3%→31.2% (2000–2022) links to psychosis treatment entry; stronger in adults ≥25 and women

• Cambridge Psychological Medicine 23-year ecological study (open-access, 4 May): THC in seized Danish resin 8.3% (2000) → 31.2% (2022) (~4×). Fully-adjusted mixed-effects linear regression on national forensic and psychiatric register data.
  • Positive associations: first-time cannabis-treatment entry (lags 0–6), cannabis-induced psychosis (lags 0–4), dual diagnosis — schizophrenia + cannabis use disorder (lags 0–1).
  • Stronger associations in adults ≥25 years (not ≤24) and in women (not men); complicates standard adolescent-risk framing; adds sex-disaggregated dimension to potency-cap debates.

🇹🇭 Thailand — FDA restricts cannabis licences to medical facilities, pharmacies and herbal-medicine shops in ~US$1bn market (16 May)

🔭 On the radar: Cannabis-and-Hemp bill public consultation closes end-May 2026; expedited parliamentary passage planned through H2. FDA licence-restriction rules (effective May 2026) push recreational dispensaries toward licence-revocation or pivot to herbal-medicine-shop registration.

🏛️ Regulation — FDA restricts cannabis licences to medical/pharmacy channels (effective May); Cannabis-and-Hemp bill in public consultation; hotline 02-257-7042 launched

• Bangkok Post 7 May: Department of Thai Traditional & Alternative Medicine opens national medical-cannabis coordination centre + hotline 02-257-7042 (weekdays 08:30–16:00); centralised complaint-handling via provincial health offices; licence-verification function targets unlicensed retail operations.
• Bangkok Post 12 May (Post Reporters): Public Health Minister Pattana Promphat signals tighter controls after 14 South Koreans arrested; denies any ‘free cannabis’ policy; frames reforms as cultivation and farm-regulation strengthening nationwide. Cannabis-and-Hemp bill in public consultation through end-May; expedited parliamentary passage planned.
• Asia News Network 16 May: FDA-led rules effective May 2026 limit cannabis licences to four purposes within medical facilities, pharmacies and herbal-medicine shops; ends broader retail sales across the ~US$1bn cannabis market. Recreational dispensaries face licence-revocation or pivot to herbal-medicine-shop registration.

🇪🇺 European Union — Commission tables hemp-leaf infusion THC limits; REGI backs hemp-flower CAP supports; EIHA pushes 1% THC ceiling

🔭 On the radar: ST 7899/2026 passes to Member State examination ahead of formal adoption later in 2026. REGI CAP hemp-flower position will take >1 year to finalise. EUDA European Drug Report 2026 launches 9 June 2026 (09:00 WEST, Brussels Berlaymont) with data from 29 countries.

🏛️ Regulation — Three converging EU hemp moves: Commission ST 7899/2026 hemp-leaf infusion THC limits (5 May); REGI CAP hemp-flower supports (15 May); EIHA 1% THC ceiling push (8 May)

• EU Commission draft regulation ST 7899/2026 (5 May): sets maximum Ι90-THC level of 1 µg/kg body weight for hemp-leaf water infusions, amending Regulation (EU) 2023/915; cites EFSA 2015 opinion as scientific basis. Council document now moves to Member State examination ahead of formal adoption later in 2026.
  • Closes EU-level regulatory gap on consumed-product THC exposure in the CBD/hemp-tea category (expanded across Italian, German and Czech markets since the 2020 CJEU ruling).
• European Parliament REGI committee backs extending CAP farm supports to CBD-rich hemp flowers (15 May): references 2020 CJEU ruling and current 0.3% THC limit (previously 0.2%); per-hectare payments vary by Member State; will take >1 year to finalise.
  • Pairs with the Commission’s prior proposal recognising the entire hemp plant (including flowers) as an agricultural product; together would give hemp flower full EU agricultural-crop status.
• EIHA / British Hemp Alliance position paper (8 May): urges EU to raise agricultural hemp THC ceiling from 0.3% to 1.0% under 2028–2032 CAP reform. Cites Switzerland, New Zealand, Australia (1%), Czech Republic (1%) and South Africa (proposed 2%) as precedents; also calls for hemp inclusion in EU marketing standards.
  • EP previously discussed 0.5% as a compromise; EIHA’s 1.0% ask would unlock breeding-pipeline diversity constrained by current low-THC genetic restrictions.

💼 Market — EUDA European Drug Report 2026 launches 9 June in Brussels; 29 countries, 100+ graphics, emerging cannabinoid markets tracked

• EUDA pre-launch notice (8 May): 9 June 2026, 09:00 WEST, Berlaymont VIP corner. Speakers: Commissioner Magnus Brunner (Internal Affairs), Franz Pietsch (EUDA Management Board Chair), Lorraine Nolan (EUDA Executive Director).
  • Data from 29 countries (EU-27, Norway, Türkiye); 100+ interactive graphics; open-access source data; 2026 Statistical Bulletin with national and city-level datasets.
  • Report scope: cannabis prevalence, seizures, market trends and emerging cannabinoid markets — likely capturing synthetic-cannabinoid dynamics visible in Denmark, Italy and Poland. Livestreamed via Europe by Satellite; embargoed access for accredited media.

🇯🇵 Japan — MHLW designates consumer CBN products as controlled substances effective 1 June; 2026 eradication campaign cites 6,342 arrests, 72.5% under-30

🔭 On the radar: CBN ministerial order takes effect 1 June 2026 — existing-stock disposal cut-off concurrent. 2026 illegal-cannabis-and-poppy eradication campaign runs through 30 June.

🏛️ Regulation — MHLW ministerial order designates consumer CBN as controlled substance (effective 1 June); 2026 eradication campaign reports 6,342 cannabis arrests in 2024, 72.5% under 30

• MHLW ministerial order: consumer CBN products designated as controlled substances effective 1 June 2026 under the Pharmaceutical and Medical Device Act; notification issued 18 March 2026 (~75-day window for existing-stock disposal. CannaReporter 7 May. Extends the HHC → THCH → CBN prohibition chain; bans manufacture, import, sale and possession.
  • Iterative-substitute pattern: each ban closes the most-recent legal-analogue product; manufacturers have historically pivoted to the next available cannabinoid within 12–18 months.
• MHLW 2026 nationwide illegal-cannabis-and-poppy eradication campaign (1 May–30 June): 6,342 cannabis arrests in 2024 (–5.4% YoY); 72.5% under 30 (+24pp since 2015). Coordinated across 8+ government bodies: prefectural governments, National Police Agency, Agency for Children and Families, Ministry of Justice, Supreme Public Prosecutors Office, MoF Customs, MEXT and Japan Coast Guard.

💼 Market — CBN ban reveals structural domestic demand; iterative prohibition cycle continues

• CannaReporter 7 May: consecutive cannabinoid bans (HHC → THCH → CBN) track persistent consumer demand in Japan that the prohibition perimeter has not extinguished; next analogue expected in consumer channel within 12–18 months of the CBN cut-off.
  • 75-day stock-disposal window may push smaller retailers out of the cannabinoid-consumer-product channel; larger operators better positioned to pivot to the next analogue.

🇳🇿 New Zealand — Industrial-hemp licensing revoked 28 May (notification-only, ≤1% THC); Medsafe export-licence processing falls to 6.4 working days

🔭 On the radar: Permission-based regime under Misuse of Drugs Regulations 1977 takes effect 28 May 2026. Medsafe weighing multi-shipment export-licence permits as next-step modernisation. Cannafis FIS (Chaco, AR) first NZ shipment in the 6.4-working-day Medsafe pipeline.

🏛️ Regulation — Industrial-hemp licensing revoked 28 May; notification-only for hemp ≤1% THC; Medsafe export-licence processing falls to 6.4 working days (from 22.5)

• NZ Ministry of Health hemp-regulation page (10 May): industrial-hemp licensing revoked 28 May 2026; replaced by permission-based regime under Misuse of Drugs Regulations 1977; licence-free cultivation, breeding, research and manufacturing for hemp ≤1% THC, subject to annual notification to NZ Police + Ministry for Primary Industries.
  • Cross-agency notification structure: NZ Police, MPI, MoH, Ministry of Justice.
• Beehive press release (9 May) (Associate Minister of Health David Seymour): Medsafe medicinal-cannabis export-licence processing 6.4 working days (down from 22.5); multi-shipment-permit proposal as next-step modernisation.
  • 49 kg → 2,310 kg flower exports 2021–2025 (~47× growth); multi-shipment permits would reduce per-licence administrative overhead.

💼 Market — Prescriptions 2% →44% of users (2020–2025); >380,000 products supplied; illicit prices −22% to NZ$286/oz; Ora Pharm acquires Helius Therapeutics out of administration

• Hemp Gazette 2 May (Steven Gothrinet): medicinal-cannabis prescriptions from 2% → 44% of users (2020–2025); >380,000 products supplied; 83% via clinics, 75% via online consults; illicit-market price −22% to NZ$286/oz; vaping use rises to 27%.
• NBR 13 May (Nicholas Pointon): Ora Pharm signs conditional SPA to acquire Helius Therapeutics out of administration (administrators Daniel Stoneman and Neale Jackson); undisclosed sum; preserves Helius assets and patient supply continuity.

🇵🇱 Poland — Sejm tables Petru/Szymanowska 15 g + 1-plant depenalisation bill (filed 28 March; committee survey 11 May)

🔭 On the radar: Petru/Szymanowska 15 g + 1-plant depenalisation bill awaits Sejm vote after the 11 May committee survey — no date scheduled. Cantourage Q2 2026 results (August) test the Polish 7.3% revenue weight. ODI Pharma Q4 FY25/26 report (August–September) anchors the SEK 29.8m nine-month run-rate against full-year comparison.

🏛️ Regulation — Petru/Szymanowska depenalisation bill (15 g + 1 plant) advances into Sejm committee work

• Fakty Konopne published the committee survey results on 11 May: MPs Ryszard Petru and Joanna Szymanowska filed the bill on 28 March 2026; framework comparable to Germany’s KCanG (15–25 g + 3 plants) and Czech possession liberalisation; secondary coverage by Gazeta Prawna and Forsal confirms mainstream business-press attention.

💼 Market — Cantourage Q1 EBITDA break-even (Poland 7.3% of €20.6m) and ODI Pharma record Q3 (SEK 12.7m) reset listed-operator benchmarks on the Polish channel

• Cantourage IR reported the Q1 2026 results on 11 May: group revenue €20.6m with the geographic split Germany 51.5% / UK 41.3% / Poland 7.3%; break-even Adjusted EBITDA versus deeper losses YoY.
• ODI Pharma IR published the Q3 FY25/26 interim report on 28 May: Q3 (Jan–Mar 2026) net sales SEK 12,712,029 (vs SEK 2,934,337 prior year), profit after financial items +SEK 126,614 (vs −SEK 340,612), result per share SEK 0.01 (vs −SEK 0.02); nine-month (Jul 2025–Mar 2026) net sales SEK 29,753,825, profit after financial items +SEK 1,417,177; solidity ratio 17% vs 11%.
• ODI Pharma: producer and representative of finished pharmaceutical cannabis products with European medical distribution.
• MJBizDaily interviewed Organigram CEO James Yamanaka on 21 May: the post-February 2026 Sanity Group acquisition opened the door to Germany, Poland and the United Kingdom; Sanity’s revenue moved from €9m in 2023 to ≈€60m in 2025 with positive EBITDA; Yamanaka cites France, Spain, Portugal and the Netherlands as the next disciplined steps; Sanity’s Polish footprint is structural rather than operational at this stage.

🇨🇿 Czech Republic — GMP-validated Czech growers reportedly rival Portugal’s Canadian-flower export value in early 2026; Buřinka awards CZK 2.5m hemp-material grants

🔭 On the radar: BfArM Q2 2026 import data will confirm or unwind the Czech/Portugal value-parity claim on Canadian medical flower. UCEEB CTU reference hemp house (CZK 2m) and FortArt reuse centre (CZK 0.5m) move into execution against 2027 climate milestones.

💼 Market — GMP-validated Czech growers reportedly rival Portugal’s Canadian-export value in early 2026; Czechia and Malta emerge as CEE alternatives to the Iberian channel

• MMJ Daily 11 May (Arnau Valdovinos): GMP-validated Czech growers reportedly rival Portugal’s Canadian medical-flower export value in early 2026; Czechia and Malta emerging as the CEE/Mediterranean alternatives to the Iberian channel alongside Spain’s GMP-validation push (Extraction Solutions, Linneo Health).
  • BfArM Q1 2026: Portugal at 20.5% / 10,342 kg; Czech volumes not broken out separately — Q2 customs data needed to validate value-parity claim.

🔬 Science — Buřinka awards CZK 2.5m in hemp building-materials grants: CZK 2m to UCEEB CTU, CZK 0.5m to FortArt (28 applicants, 18 May)

• EnviWeb 18 May (via PROTEXT ČTK Connect): Buřinka awards CZK 2m to UCEEB CTU for a working reference hemp house + hemp building-element R&D; CZK 0.5m to FortArt for a circular-economy construction-material reuse centre using hemp-fibre inputs. 28 applicants; 7-member jury; projects framed against Czech 2027 climate-goal milestones.

🇨🇴 Colombia — Adult-use bill 023/2025C clears House First Committee (13 May); most concrete legalisation progress since 2023 Senate failure

🔭 On the radar: Bill still requires full Chamber vote and two Senate readings — multiple veto points ahead. Tax-revenue earmarks (health and education) and minor/vulnerable-community protections carry over from 2023 framework. Decreto 1138/2025 medical-flower framework active in background.

🏛️ Regulation — House First Committee approves seed-to-sale adult-use bill 023/2025C; proceeds to full Chamber + two Senate votes

• Marijuana Moment (13 May): House of Representatives First Committee approves Rep Alejandro Ocampo’s bill 023/2025C; mandates ID checks, point-of-sale licensing and permitting; proceeds to full Chamber, then two Senate readings.
  • Seed-to-sale regulated-market design (not decriminalisation only); ID checks, permits and POS licensing form the compliance backbone.
• canamo.net 18 May: bill includes licensing, advertising limits, consumption restrictions; tax revenue earmarked for health and education; explicit minor/vulnerable-community safeguards.
  • Hemp Gazette 14 May: additional procedural confirmation of the committee advance.

🇦🇷 Argentina — REPROCANN AI cuts approvals to ~24h (500→1,300 monthly intake); Cannafis ships first private medicinal export to New Zealand

🔭 On the radar: REPROCANN AI intake 500→1,300/month; throughput test continues through August. ARICCAME intervention ends September, opening a production window across Misiones, Tierra del Fuego and San Luis. Cannafis FIS (Chaco) first NZ shipment into Medsafe’s 6.4-day pipeline.

🏛️ Regulation — Ministerio de Salud AI-driven REPROCANN cuts approvals from years to ~24h; Tierra del Fuego GACP/GMP registry; Bregman/Del Caño legalisation bill (30 May)

• MisionesOnline 29 May: Ministerio de Salud AI-driven REPROCANN cuts approval times from years to ~24h; monthly intake 500→1,300+ on cumulative 20,000+ user base; 61% pre-consuming cannabis before registration; >80% using REPROCANN as their sole medical touchpoint.
• Radio Sativa 26 May: Tierra del Fuego registers 4,200+ REPROCANN users under Provincial Law 1277/2019 + Decree 2605/25; GACP/GMP-aligned cannabis registry launched. Cross-institutional: Ministerio de Producción y Ambiente + Ministerio de Salud (TdF), INTA, UTN, UNTDF, CADIC, CONICET.
• Radio Sativa 30 May: Diputados Bregman & Del Caño (Frente de Izquierda) introduce comprehensive cannabis legalisation bill; reclassifies cannabis, permits self-cultivation and social clubs; supersedes Ley 23.737; ANMAT as implementing authority. Bill introduced, not enacted.
• Radio Sativa 23 May: Patagonia federal operativo over 2g cannabis on a Bariloche-Esquel coach exposes contradictions between Ley 27.350 / Ley 27.669 and 1989 narcotics-law enforcement practice.

💼 Market — Cannafis FIS (Chaco) ships first private Argentine medicinal export to New Zealand; Bifábrica Misiones 2026 harvest; MisioPharma targets >1,000 bottles

• Chaco provincial government 28 May: Cannafis FIS S.A.S. (Chaco) ships first private Argentine medicinal cannabis export to New Zealand; NZ destination = Medsafe-regulated market with 6.4-working-day processing window; NZ flower exports reached 2,310 kg in FY 2024/25.
• HortiDaily 8 May: Bifábrica Misiones 2026 harvest underway; hybrid model, 40–50 cm intake height. Cannábica Argentina 22 May (Romina Guilarducci): MisioPharma targets >1,000 bottles of medical-cannabis oil under ARICCAME/ANMAT oversight; ARICCAME intervention ends September.

🔬 Science — UNLP, UNAJ (2,000+ registrants) and UNSL formalise cannabis research and pharma-grade R&D agreements

• Radio Sativa 6 May: UNLP formal agreement links La Semilla Colectivo Cannabico, AnandaCan, Medicina Cannábica, Villa Alba Cultiva, Clon.AR and Cultivar Ciencia Argentina; first AR university–civil-society research linkage in a regulated REPROCANN frame.
• Radio Sativa 8 May: UNAJ II Congreso Internacional de Cáñamo y Cannabis (2,000+ registrants): clinical advances in rheumatology, metabolic syndrome, paediatrics, dentistry and psychedelics; FAUBA and INTA representation; Diputada Carolina Gaillard and Defensora Victoria Vaca Paunero. One of the largest LatAm cannabis-science gatherings of 2026.
• Radio Sativa 15 May: UNSL / INFOMAC (San Luis): strategic biopharma-pipeline R&D agreement; 400 MHz NMR + chemotype-3 analytical setup; positions San Luis as the analytical anchor for Argentina’s pharma-cannabis export ambitions alongside the Chaco/Misiones production base.

🇨🇱 Chile — Ley 21.817 published 23 May modifies Ley 20.000; 37 diputados file Tribunal Constitucional challenge over small-quantity trafficking provisions

🔭 On the radar: TC ruling timing is the operative variable for cannabis-user exposure under Ley 21.817; publication date 23 May 2026 starts the enforcement clock. A TC ruling against the small-quantity provisions would carve out cannabis self-cultivation from the reform’s reach.

🏛️ Regulation — Ley 21.817 (published 23 May) modifies Ley 20.000 with trafficking aggravantes; 37 diputados file TC challenge over small-quantity provisions

• El Mostrador 3 June investigation: Ley 21.817 published 23 May 2026 modifies Ley 20.000; tightens aggravantes around trafficking. Original moción filed September 2022 by senadores Manuel José Ossandón (RN), José Miguel Insulza (PS), Francisco Huenchumilla (DC), Jaime Quintana (PPD) and Kenneth Pugh (IND/RN).
  • Aggravantes language risk: small-quantity cannabis possession provisions can be read as exposing self-cultivators and REPROCANN-equivalent medicinal users to trafficking-grade sanctions — a partial re-closing of the small-quantity/bulk-trafficking distinction established by Ley 20.000 in 2005.
• El Planteo analysis: 37 diputados filed Tribunal Constitucional challenge against the small-quantity penalty provisions; TC ruling will determine whether those provisions survive constitutional review.

🇵🇹 Portugal — Infarmed reset removes >30% of licensed operators; Portugal supplies 10,342 kg (20%) of Germany’s Q1 medical imports

🔭 On the radar: BfArM Q2 2026 import data will be the first quarterly read on whether the Infarmed January–May licence reset flows through to Portuguese export volumes (Q1: 10,342 kg, 20% share). Net Infarmed licence count recovering off the May trough after 19 May re-instatements of Tilray, Canna.Biz and Ahara. INFARMED-framed demand-side activation (prescriber education, reimbursement, GP access) identified as Portugal’s next policy lever.

🏛️ Regulation — Infarmed lists show >30% of licensed operators suspended or removed since January 2026; selective re-licensing of Tilray, Canna.Biz and Ahara on 19 May confirms administrative reset

• CannaReporter 11 May (António João Costa): cultivation licences –36%, export –27%, import –25% since January. Company counts: importers 49→36, exporters 48→34, cultivators 39→25, manufacturers 27→23, 12 wholesalers.
  • Every chain step hit simultaneously (cultivation, manufacturing, import, export) — consistent with administrative housekeeping (licence-renewal lapses), not targeted compliance enforcement.
  • Syenza secondary analysis: cumulative >40% active-licence drop flagged as risk to Portugal’s role as Europe’s primary processing hub; warns of supply-chain disruption and reduced foreign investment.
• CannaReporter 19 May: authorisations rebound to 39 import, 37 export, 28 cultivation, 25 manufacturing; confirms January–April removals were expired authorisations, not regulatory infractions.
  • Tilray, Canna.Biz and Ahara reinstated 19 May. Tilray’s return especially material given its EU-GMP supply chain role into Germany.
• CannaReporter 20 May exclusive: INCB letter and annex reproduced; classifies uncontrolled cannabinoid extraction as industrial hemp; calls for tighter licensing, monitoring and reporting; flags capacity constraints at national authorities — directly relevant to Infarmed’s reset.

💼 Market — Portugal 10,342 kg (20%) of Germany’s Q1 imports despite domestic contraction; INCENTEA: 60–80 t/year installed capacity vs ~750 active prescriptions

• StratCann BfArM Q1 data: Germany imported 50,539 kg in Q1 2026, exported 1,526 kg; Portugal 10,342 kg (20.5% share); volume down 15% QoQ but +34% YoY. May licence contraction did not yet flow through to export volumes — Q2 will be the first affected quarter.
  • Domestic licence count: 3 German producers, 2 linked to Tilray/Aphria and Aurora; EU-GMP “washing” via Portugal noted for German patients.
  • Arnau Valdovinos MMJ Daily interview (11 May): Czechia’s GMP-validated growers now rivalling Portugal’s Canadian export value in early 2026; Malta sourcing from Israel, South Africa and Canada — EU GMP supply chain diversifying.
• INCENTEA write-up: regulator José Vera Cruz and PortoCanna CEO Amit Edri map gap between installed capacity (60–80 t/year) and real-world use (~750 active prescriptions, >150,000 potential patients). SAGE and Order of Pharmacists urge demand-side policy change (prescriber education, reimbursement, GP access).

🔬 Science — INFARMED frames clinical research as Portugal’s next growth pillar; sole authorised trial: chronic neuropathic pain in MS

• SaudeOnline.pt 18 May (Maria João Garcia): INFARMED frames medicinal-cannabis clinical research as having “enormous growth potential”; Portugal positioned to scale under EU Clinical Trials Regulation 536/2014 and Law No 09/2026.
  • 1 authorised cannabis clinical trial in Portugal: chronic neuropathic pain in multiple sclerosis.
  • Supply-side licensing in contraction; domestic prescriptions far below capacity; INFARMED frames clinical research as the structural growth lever.

🇿🇦 South Africa — Cannabis Expo 2026 Sandton +30% YoY; Cannabis Act two years on with regulations still draft; Stellenbosch identifies first flavoalkaloids in Cannabis

🔭 On the radar: Prince application hearing 8 June 2026 (Western Cape High Court). DoJ&CD draft regulations finalisation pending the 5-plant vs 3,000-plant Mpondoland gap. R28bn export ambition contingent on seed-import, accredited-lab and GMP-support infrastructure through H2 2026.

🏛️ Regulation — Cannabis Act two years on: DoJ&CD Feb 2026 draft sets 5-plant limit (150+ submissions; 3,000-plant Mpondoland proposal unaddressed); Prince hearing 8 June 2026

• Cannabiz Africa 27 May (Brett Hilton-Barber): two years after Cannabis Act signature (28 May 2024), licensing decrees remain unfinalised. DoJ&CD Feb 2026 draft: 5-plant home-grow limit vs unresolved 3,000-plant Mpondoland traditional-cultivator proposal; 150+ submissions received. Prince hearing 8 June 2026 (Western Cape High Court) tests constitutional standing of the 5-plant limit. R28bn export ambition vs current R14bn regulated-market base.

💼 Market — Cannabis Expo 2026 Sandton +30% YoY; BioCann pairs Segra International genetics + EU-GMP equipment for DE/UK/AU exports; R2.8bn–R14bn shortfall quantified

• Sunday World 14 May: Cannabis Expo 2026 Sandton (29–31 May) posts +30% YoY exhibitor and ticket growth; SAHPRA and DTIC on programme; regulated market base >R14bn / >R30bn including informal.
• MMJ Daily 20 May: BioCann — 100-ha farm (7 ha licensed), Segra International (Health Canada-registered) genetics, EU-GMP equipment installed; exporting to Germany, UK and Australia; CEO Woody Chammas, GM Shaq Badat.
• BusinessDay 29 May (Charl Botha, H3 Legal Solutions): R14bn baseline vs R28bn projection; R2.8bn–R14bn shortfall depending on 10%–50% growth target; gaps: seed-import delays, accredited-lab gaps, GMP-support deficiencies. Urges expedited regulatory pathways across SAHPRA, Department of Agriculture, DTIC, Customs and provincial authorities.

🔬 Science — Stellenbosch University (Muller, de Villiers, Journal of Chromatography A): 79 phenolics in three SA Cannabis strains including 25 newly reported and 16 tentative flavoalkaloids — first identification of flavoalkaloids in Cannabis leaves

• ScienceDaily 1 May (Magriet Muller + André de Villiers, Stellenbosch University; Journal of Chromatography A): 79 phenolic compounds across three South African Cannabis strains; 25 newly reported; 16 tentative flavoalkaloids — first identification of this chemical class in Cannabis leaves. Leaf-material focus: discarded leaf biomass as potential pharmaceutical input. >750 Cannabis metabolites now known.

🇺🇾 Uruguay — Frente Amplio proposes ‘hybrid’ overhaul dropping IRCCA registration and adding sale points; pharmacy sales +30–65% YoY

🔭 On the radar: Orsi government hybrid-model proposal (drop mandatory IRCCA registration, expand sale points) at policy-floating stage — no draft bill text yet. Cultivator base scales 3→7 under new 10-year licences. IRCCA tourist/day-pass proposal pending primary-source confirmation.

🏛️ Regulation — Frente Amplio proposes ‘hybrid’ overhaul: drop mandatory IRCCA registration, add sale points beyond pharmacies; IRCCA floats tourist day-pass [unverified]

• El País Uruguay 28 May: Frente Amplio (Orsi government) proposes ‘hybrid’ overhaul of the 2013 framework: remove mandatory IRCCA user registration; create new sale points beyond the pharmacy channel. Policy-floating stage — no draft bill text published.
• Rio Times Online 6 May [unverified — single secondary-outlet source]: IRCCA proposes temporary-registration/day-pass system granting non-residents legal adult-use access under new executive director Martín Rodríguez. Primary IRCCA confirmation pending.

💼 Market — IRCCA Q1 2026: 120,083 users, pharmacy sales +30–65% YoY; 4 new cultivation licences double producer base to 7; exports to Germany, Switzerland, Brazil

• Montevideo Portal 14 May: IRCCA Q1 2026: 120,083 registered users (88,955 pharmacy purchasers + 20,798 club members); Q1 pharmacy sales >1.9 million g (+30–65% YoY) across 60 dispensing pharmacies; active autocultivadores fall to 10,330; 448 inspections, 19 sanctions. Distribution expanding across Montevideo, Canelones and Maldonado.
• Ámbito 15 May: IRCCA awards 10-year cultivation licences to Turigrow SAS, Tested SAS, Calgrey SA and Flores del Plata SAS — cultivator base doubles from 3 to 7; from an 8-licence tender (Empresa Patria disqualified).
• AmericaMalls & Retail 20 May: 100+ active cannabis initiatives; ~6 t/year capacity across 5 IRCCA cultivation licences (3 active); outbound flows to Germany (medical pharmacy), Switzerland (EU-adjacent supply) and Brazil (ANVISA-permitted imports); 2025 domestic pharmacy sales >9 t (4,290 kg).

🇲🇰 North Macedonia — Replek reports first EU medical-cannabis export after 10 years; Purely Plant claims GMP pass [unverified]

🔭 On the radar: Purely Plant local-GMP and CUMCS claim pending regulator-side or trade-press confirmation — EU-GMP (the harder threshold) not yet claimed. Replek H2 2026 EU-export volume data to test whether the export channel opens at scale.

💼 Market — Replek marks 10 years and first EU medical-cannabis export (15 May); Purely Plant clears local GMP + 3 CUMCS certifications with zero observations [unverified] (29 May)

• eMagazin.mk 15 May: Replek (Skopje) marks 10 years of medical-cannabis production since 2016; first export of medical-cannabis products to the EU. Portfolio: CBD oils, cosmetics, CBD/THC therapies; supercritical CO₂ extraction; pharma-grade standards.
• LinkedIn 29 May (GM Zlatko Keskovski) [unverified — single LinkedIn self-announcement]: Purely Plant GmbH clears local GMP inspection + 3 CUMCS certifications with zero observations. EU-GMP certification not yet claimed; MALMED/CUMCS registers to be cross-referenced.

🇲🇹 Malta — ARUC permits solventless resin under CHRA framework (1 g resin = 3 g flower equivalency, 6 May)

🔭 On the radar: Q2 2026 BfArM and Maltese customs data due to validate the Malta-as-EU-supply-node thesis.

🏛️ Regulation — ARUC amends CHRA framework: solventless resin permitted (1 g resin = 3 g flower equivalency); personal caps unchanged at 7 g/day + 50 g/month

• ARUC 6 May: ARUC permits Cannabis Harm Reduction Associations to produce and distribute solventless cannabis resin; 1 g resin = 3 g flower equivalency under existing personal caps (7 g/day + 50 g/month combined flower-resin). Framed as harm-reduction substitute for illicit-market hashish.
  • Solventless restriction excludes hash-oils, BHO and solvent-extracted concentrates; covers dry-sift and water/ice-water resin methods only.

💼 Market — Malta cited as Israel/South Africa/Canada sourcing destination in EU supply-chain diversification piece (11 May)

• MMJ Daily 11 May (Arnau Valdovinos): Malta and Czechia named as emerging Central/Mediterranean nodes in the diversifying EU-GMP supply chain; Maltese GMP-validated facilities source from Israel, South Africa and Canada for EU export onward.

🇮🇪 Ireland — HRB Drug Treatment Bulletin 2025: cannabis 3rd most-treated drug (15.1%); HHC cases up >400% to 256

🔭 On the radar: EUDA European Drug Report 2026 launches Brussels 9 June — will place Ireland’s HHC surge and under-19 cannabis-demand pattern in cross-EU context.

🔬 Science — HRB Drug Treatment Bulletin 2025 (1 May): cannabis 3rd most-treated main drug (15.1%); HHC cases +>400% to 256; total cannabis-related cases 9,535 (61.8%)

• HRB Drug Treatment Bulletin 2025 PDF (published 1 May 2026): cannabis 3rd most-treated main drug at 15.1% of cases; cannabinoid NPS (HHC) cases +>400% to 256; total cannabis-related use cases 9,535 (61.8% of all reported drug-use cases). Cohort split: under-19s cite cannabis; 20–44s cite cocaine; 45+ cite opioids. Pregabalin: 191 cases (1.2%).

🇰🇷 South Korea — MFDS biannual inspections target 55 substances including CBD and THC across 4,653 listed hazardous products; Daegu Hemp Industry Cluster KRW 802m tender

🔭 On the radar: MFDS inspection cycle runs May–June 2026; next cycle November–December 2026. Daegu Hemp Industry Cluster electrical-works tender (bids closed 8 May) moves the cluster into construction phase.

🏛️ Regulation — MFDS launches biannual inspections of overseas direct-purchase foods targeting 55 narcotic-related substances incl. CBD, THC, fentanyl and mitragynine (11–12 May)

• Seoul Economic Daily 11 May + 12 May follow-up: MFDS biannual inspections of overseas direct-purchase foods; 55 narcotic-related substances (incl. CBD, THC, fentanyl, amphetamine, mitragynine); 312 banned raw materials, 22 narcotics, 4,653 listed hazardous products; May–June 2026 focus: gummies, beverages and candies. Joint operation with Korea Customs Service and Korea Communications Standards Commission; confirmed cases referred for blocking and removal.

💼 Market — Public Procurement Service tenders KRW 802.34m for Daegu Hemp Industry Cluster electrical works (6 May)

• KoreaTenders 6 May (ref 139373489): KRW 802.34m tender for electrical works on the Daegu Hemp Industry Cluster + Special Crop Industrialisation Support Centre; bids due 8 May 2026. Gyeongsangbuk-do hemp-industrialisation strategy; cluster moves from planning to construction stage.

🇨🇷 Costa Rica — Bioxyne ships first international medicinal-flower SKUs >US$500k via Remidose; first EU export under Law 10113 amplified through May press

🔭 On the radar: Bioxyne first international flower SKU shipment to Costa Rica due before 30 June 2026. Future Dr Watson pastille deliveries to Panama scoped. Law 10113 first-EU-export claim pending COMEX customs or operator-side primary confirmation.

💼 Market — Bioxyne expands Remidose agreement for three Dr Watson flower SKUs >US$500k to Costa Rica (first international flower shipment); first EU export under Law 10113 [unverified] (11 May)

• Bioxyne ASX announcement 11 May: Bioxyne (via Breathe Life Sciences) expands Dec 2025 agreement with Remidose to supply three Dr Watson cannabis-flower SKUs to Costa Rica; expected before 30 June 2026; invoice >US$500,000; first international medicinal-flower shipment. Future Dr Watson pastille deliveries to Panama scoped.
• Astute Analytica / Globe Newswire 11 May [unverified]: Hybrida Farms (Vantage Point Global CR S.A.) completed Costa Rica’s first commercial medical-cannabis export to the EU under Law 10113 on 13 March 2026; PROCOMER-registered exporter; GACP-certified; dual-licensed for THC medical + industrial hemp under MAG, Ministry of Health and ICD oversight. Destination Member State and shipment value undisclosed.

🇵🇾 Paraguay — May 2026: Discovery surfaced DINAVISA Resolución 182/2026 (reference-authorities list for medical-cannabis registration under Law 6007/2017, 28 May) via Phase X gap-scan, but the News DB items for this resolution point at the DINAVISA homepage only and carry `needs_review = YES` — failing the 3-strike source-verification rubric; brief parked pending primary DINAVISA PDF or Gaceta Oficial publication

🔭 On the radar: The DINAVISA reference-authorities list, if confirmed, would clarify the import-pathway for medical-cannabis derivatives under Law 6007/2017 — a material regulatory-clarity step for Paraguayan operators. Web cross-search surfaced DINAVISA Resolución 488/2026 (Feb 2026 pilot scheme) and Feb 2026 framework-update reporting, but did not locate the specific 182/2026 publication URL. Re-check DINAVISA’s resolutions page and Gaceta Oficial for the 28 May publication.

🏛️ Regulation — No verified primary-source News DB item for May 2026; Discovery surfaced DINAVISA Resolución 182/2026 (reference-authorities list for medical-cannabis registration under Law 6007/2017, dated 28 May 2026), but the News DB rows for this item carry homepage-only URLs (`dinavisa.gov.py/`) and `needs_review = YES`, triggering 3 strikes (slug mismatch + duplicate URL + needs-review) under the verification rubric and excluding them from the brief body

Paraguay’s May 2026 file currently has no News DB item that meets the source-verification threshold. The Phase X gap-scan referenced a DINAVISA Resolución 182/2026 establishing a reference-authorities list under Law 6007/2017, dated 28 May 2026, but no primary DINAVISA PDF or Gaceta Oficial entry has been located to verify the resolution number, scope or publication date.

Brief held in parked status pending primary-source verification of DINAVISA Resolución 182/2026. Verification path: (a) check DINAVISA’s resolutions page for the specific Resolución 182/2026 PDF; (b) cross-check the Paraguayan Gaceta Oficial publication dated 28 May 2026; (c) check trade-press follow-up reporting (`infonegocios.com.py`, `hoy.com.py`) for a 182/2026 reference. If verified, the resolution will be added to the brief body with the primary URL.

• Adjacent verified context: DINAVISA Resolución N° 488/2026 (primary PDF, Feb 2026) established a 2-year pilot for medicinal-cannabis-product commercialisation — the regulatory framework into which any 182/2026 reference-authorities list would slot.
• DINAVISA acts as Paraguay’s national medicines-and-medical-devices regulator (Dirección Nacional de Vigilancia Sanitaria); medical-cannabis registration sits under its remit since the 2017 framework launch.

🇮🇳 India — Panda Biotech and Culturewell launch India’s first integrated hemp fibre-to-yarn supply chain (US-grown fibre upstream, Indian degumming + spinning downstream)

🔭 On the radar: OEKO-TEX Standard 100 + USDA BioPreferred certifications targeting B2B export-grade buyers. State-level hemp-pilot scaling under NDPS Act constraints remains the gating factor for Indian-grown fibre integration.

💼 Market — Panda Biotech + Culturewell: India’s first integrated hemp fibre-to-yarn supply chain; 6s–30s fibre, 20s–30s ring-spun yarn, blends up to 100% (21 May)

• Panda Biotech press release 21 May: Panda Biotech + Culturewell Trading LLP launch India’s first integrated hemp fibre-to-yarn supply chain; US-grown mechanically cottonised hemp upstream; Indian degumming + spinning downstream; 6s–30s fibre, 20s–30s ring-spun yarn; blends up to 100%. Certifications: OEKO-TEX Standard 100 + USDA BioPreferred.
  • Note: US-grown upstream fibre reflects ongoing Indian-cultivation constraints under the NDPS Act. Domestic-fibre integration awaits state-level hemp-pilot scaling delivering EU-/USDA-grade traceability.

🇬🇭 Ghana — NACOC begins issuing cannabis cultivation licences (≤0.3% THC); West Africa’s largest regulated market opens

🔭 On the radar: NACOC licence-issuance uptake rate against the ≤0.3% THC ceiling will signal whether industrial-hemp + low-THC medicinal can support West African export ambition. Ghana Standards Authority testing throughput is the next operational bottleneck. Cannabis Licensing Authority Board follow-up sessions expected through Q3.

🏛️ Regulation — NACOC formally launches medicinal and industrial cannabis cultivation licensing (≤0.3% THC) under Minister for Interior; first authorised farm at Samahu; Cannabis Licensing Authority Board first meeting 8 May (May 2026)

• NACOC cannabis-regulations page + Ministry of Interior announcement: NACOC formally launches medicinal and industrial cannabis cultivation licensing in May 2026; limited to ≤0.3% THC; first authorised farm at Samahu; framework approved by Parliament ahead of NACOC’s 11 February 2026 announcement.
  • Cannabis Licensing Authority Board first meeting 8 May 2026; Ghana Standards Authority (GSA) testing pipeline operational since October 2025. Ghana’s ~34m population: largest West African cannabis-licensing rollout to date.

🇯🇲 Jamaica — CLA launches Medical Cannabis Special Permit Programmes for small farmers and retailers; legal market USD 63.5m (+63% YoY)

🔭 On the radar: CLA Special Permit Programme uptake by small farmers and retailers to be measured over the next 6–12 months. CLA annual-report data due to validate the 200-licence and USD 63.5m market-value figures.

🏛️ Regulation — CLA launches Medical Cannabis Special Permit Programmes for small farmers and retailers (8 May); legal market USD 63.5m (+63% YoY)

• MIIC/CLA 8 May: Cannabis Licensing Authority (CLA) Board launches Medical Cannabis Special Permit Programmes for small farmers and retailers under 2025 amendment regulations; legal-market value USD 63.5m in 2025 (up from USD 38.9m in 2024, +63% YoY); nearly 200 licences issued under CLA framework to date. New permit categories provide lower-cost routes for small farmers and retailers.

🇨🇳 China — Complete CBD biosynthesis pathway reconstituted in N. benthamiana at 9 µg/mg DW; Shandong phytoliths date Cannabis to Neolithic

🔭 On the radar: Fu Wang et al. CBD-pathway reconstitution signals next-step enzyme optimisation and titre improvement as the commercial scale-up route. No regulatory or market moves: China’s restrictive cannabis perimeter holds.

🔬 Science — CBD biosynthesis pathway reconstituted in Nicotiana benthamiana (9 µg/mg DW, 5 core enzymes, 128 pathway genes; 15 May); Shandong phytoliths place Cannabis at staple-crop frequency 4500–3400 BP (6 May)

• Industrial Crops and Products — Fu Wang et al. 15 May (CC BY-NC-ND 4.0): CBD biosynthesis pathway reconstituted in Nicotiana benthamiana via 2A peptide multigene system co-expressing 5 core Cannabis sativa enzymes; yield 9 µg CBD per mg dry weight; 128 pathway genes identified across 5 families. First complete plant-based CBD biosynthesis reconstruction in a non-cannabis chassis.
• Journal of Archaeological Science — Xu Liu et al. 6 May: Shandong phytolith study (Beitaishang + Qianzhongzitou sites); Cannabis phytolith ubiquity >50% at 4500–3400 BP; 84–100% co-occurrence with staple cereals (foxtail millet, broomcorn millet); diagnostic Tabular sinuate verrucate and psilate types; (10.2 ± 0.4) × 10⁶ g⁻¹. Cannabis integrated into prehistoric Shandong crop assemblage at staple-crop frequency.

🇵🇰 Pakistan — ECC tops up CCRA HQ refurbishment to Rs200m; CCRA briefs Khyber Pakhtunkhwa tribal leaders on National Cannabis Policy (May 2026)

🔭 On the radar: CCRA Islamabad HQ operationalisation through Q3 2026; Rs200m funded (original Rs1bn ask 80% unfunded). CCRA 13-member board to issue first five-year licences post-HQ completion.

🏛️ Regulation — CCRA briefs KP tribal leaders on National Cannabis Policy; ECC tops up CCRA HQ refurbishment to Rs200m, unblocking 13-member board’s five-year licensing powers

• MMJ Daily 6 May: CCRA briefs Khyber Pakhtunkhwa tribal leaders on 2026 National Cannabis Policy framework; licensing for medical and industrial cultivation, processing and export; set quotas, fees and quality standards. DG Maj Gen (R) Zafarullah Khan; Cabinet Division parent.
• Pakistan Today 8 May: ECC approves additional Rs100m, raising CCRA Islamabad HQ refurbishment budget to Rs200m (vs Rs1bn original ask); Finance Division FY2025–26 allocation; 13-member board empowered to issue 5-year licences. Cross-ministry coordination: Cabinet Division, Defence Division Secretary.

🇱🇧 Lebanon — Sixth Bekaa Valley season opens before CRA licensing decrees finalised; IMF puts regulated market at US$1–3bn

🔭 On the radar: CRA licensing decree approvals expected June–July 2026. Structural test: whether the 2027 season opens under a regulated framework or repeats the 2026 illicit-default pattern.

🏛️ Regulation — CRA Director Dany Fadel: 2026 Bekaa Valley season opens before licensing decrees finalised — sixth year since Law 178/2020; thousands of Hermel and Baalbek farmers continuing clandestine cultivation

• Al-Modon 13 May (cross-referenced L’Orient Today + Cannareporter): CRA Director Dany Fadel warns 2026 Bekaa Valley season opens before CRA licensing decrees are finalised — six years after Law 178/2020; thousands of Hermel and Baalbek farmers continuing clandestine cultivation. IMF estimate: US$1–3 billion/year regulated-market potential.

🇰🇪 Kenya — High Court scheduled to rule 28 May on Rastafarian-led constitutional challenge to cannabis religious use

🔭 On the radar: Ruling outcome surfaces in the June 2026 brief. Both directions carry regional consequences for East African drug-law and religious-rights policy.

🏛️ Regulation — High Court of Kenya (Justice Bahati Mwamuye) scheduled to rule 28 May 2026 on 2021 Rastafarian constitutional challenge; NACADA and State oppose

• The Star Kenya 12 May: Rastafari Society of Kenya + Mwendwa Wambua (Ras Prophet) filed 2021 constitutional challenge to cannabis-use restrictions for religious rites; lawyers Shadrack Wambui + Alexander Mwendwa; NACADA joined as interested party (January 2026); State opposing. Ruling scheduled 28 May 2026 (Justice Bahati Mwamuye). East African religious-rights and drug-law precedent at stake.

🇮🇷 Iran — First GWAS of 145 Iranian Cannabis landraces maps 91 loci across 233k SNPs (The Plant Genome, 8 May)

🔭 On the radar: 145-landrace, 233k-SNP germplasm pool released into global Cannabis breeding pipelines; 91 genomic regions and 15 pleiotropic loci available as marker-assisted-breeding targets. 1988 Anti-Narcotics Law remains in force; no medical-cannabis programme.

🔬 Science — GWAS of 145 Iranian Cannabis landraces (233,000 SNPs): 91 genomic regions, 15 pleiotropic loci (Babaei + Torkamaneh, The Plant Genome, 8 May)

• The Plant Genome — Babaei & Torkamaneh 8 May: GWAS of 145 Iranian Cannabis landraces using 233,000 SNPs; identifies 91 genomic regions and 15 pleiotropic loci controlling phenological, morphological and phytochemical traits. Largest published Iranian-landrace germplasm characterisation; marker-assisted-breeding targets span flowering time, architecture and cannabinoid/terpene traits simultaneously.
  • Iranian landrace population: one of the most diverse Cannabis germplasm pools in Eurasia. No regulatory or market context: 1988 Anti-Narcotics Law remains in force; no medical-cannabis programme.

🇱🇸 Lesotho — Regulator overhauls medicinal-cannabis oversight to defend sole African API-grade EU-exporter lead [unverified]

🔭 On the radar: New Lesotho licensing and inspection regulations expected to be gazetted June–July 2026. Competitive position being tested against Morocco (Law 13-21 approvals), Zambia (new ZAMRA-led committee) and Zimbabwe (longstanding export licensing).

🏛️ Regulation — Lesotho overhauls medicinal-cannabis oversight ahead of new licensing and inspection regulations [unverified]; framework: 2018 Drugs of Abuse (Cannabis) Regulations + 2025 amendment

• Cannabiz Africa 6 May: Lesotho overhauls medicinal-cannabis oversight ahead of new licensing and inspection regulations; framework: 2018 Drugs of Abuse (Cannabis) Regulations + 2025 amendment. Positioned as Africa’s sole API-grade EU exporter; overhaul targets competitive defence against Morocco, Zambia and Zimbabwe entrants. Watch for gazettement June–July 2026.

🇿🇲 Zambia — ZAMRA leads new National Cannabis Coordinating Committee, replacing Zambia Defence Force National Service de facto monopoly (6 May)

🔭 On the radar: Medical-protocol drafts and medical-insurance coverage rules expected through Q3 2026. 10-year licence framework rolls out under new cross-ministerial design.

🏛️ Regulation — ZAMRA leads National Cannabis Coordinating Committee: replaces ZDF National Service monopoly; cannabis integrated into public-health and medical-insurance system; 10-year licences; $0-budget structure

• Cannabiz Africa 6 May (John Makoni): Zambia Medicines Regulatory Authority (ZAMRA) leads new National Cannabis Coordinating Committee, replacing the Zambia Defence Force National Service de facto monopoly. Cannabis explicitly integrated into the public-health system; draft protocols for medical integration and medical-insurance coverage; 10 part-time members; 10-year licences; $0-budget structural shift. Cross-ministerial: Home Affairs, Commerce/Trade/Industry, Defence, DEC, Justice, Lands, Agriculture, Health.

🇲🇦 Morocco — ANRAC reports 67 approved cannabis products under Law 13-21, first legal cannabis exports, and 2025 production of 19,576 quintals (1,957.6 tonnes) across 5,765 active permits [all figures unverified — ANRAC homepage URL only, no primary publication located]

🔭 On the radar: Phase X gap-scan and News-DB items both reference ANRAC’s May 2026 reporting (67 approved products + first legal exports + 19,576 quintals 2025 production + 5,765 active permits under Law 13-21), but neither News-DB row carries a publication-specific URL beyond the `anrac.ma` homepage. Treat the figures as ANRAC-stated only until primary publication or Moroccan Official Bulletin entry surfaces. The structural direction (regulator-side product-approval scale + first export milestones + 4.1% YoY production growth) is consistent with prior-month trajectory.

🏛️ Regulation — ANRAC reports 67 cannabis-product approvals under Law 13-21 + completion of Morocco’s first legal cannabis exports + 2025 production of 19,576 quintals (1,957.6 tonnes) across 5,765 active permits [all figures unverified — ANRAC homepage URL only, no primary publication located] (15 May)

May’s regulatory file references a substantial ANRAC reporting moment — 67 approved products under Law 13-21, the first legal cannabis exports, and 2025 production volumes — but the News-DB rows for these claims point only to the ANRAC homepage, with no publication-specific URL surfaced. The figures are carried as ANRAC-stated only.

ANRAC reports 67 approved cannabis products under Law 13-21, completion of Morocco’s first legal cannabis exports, and 2025 production of 19,576 quintals (1,957.6 tonnes) across 5,765 active permits [all figures unverified — ANRAC homepage URL only, no primary publication located]. Primary verification path: (a) ANRAC’s official communiqués / annual report URL; (b) Moroccan Official Bulletin (Bulletin Officiel) for export-authorisation publications; (c) trade-press follow-up coverage (Le360, Hespress, Yabiladi).

• The 67-product approval figure, if confirmed, would be the largest single-month product-portfolio expansion published under Law 13-21 since the framework’s launch; downstream commercial supply readiness depends on the operator mix behind the approvals.
• 19,576 quintals (1,957.6 tonnes) 2025 production at 5,765 active permits implies ~340 kg per permit on average — consistent with the smallholder-permit structure under Law 13-21 in the three legal-cultivation provinces (Al Hoceima, Chefchaouen, Taounate).
• The first-legal-exports claim is the structurally significant milestone of the month if confirmed; the destination market(s) and operator(s) are not specified in the News-DB rows. Primary publication will determine whether the exports are extract-based (CBD oils, isolate) or finished-pharmaceutical-grade.